(Former name, former address and former three months, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

As of ~~August 16, 2021,~~May 17, 2022, there were ~~17,318,486~~19,106,625 shares issued and ~~16,968,140~~18,719,201 shares outstanding of the registrant’s common stock.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY


																Accumulated
																Other																										Accumulated
	Common Stock				Additional		Treasury Stock									Comprehensive			Total			Preferred Stock				Common Stock				Additional			Treasury Stock									Other			Total
	No. of Shares		Value		Paid-in Capital		No. of Shares			Value			Accumulated Deficit			Income (Loss)			Stockholders' Deficit			No. of Shares		Value		No. of Shares		Value		Paid-in Capital			No. of Shares			Value			Accumulated Deficit			Comprehensive Income (Loss)			Stockholders' Deficit

Balance at January 1, 2021		13,485,128	$	13,484	$	14,333,285		(415,328	)	$	(611,854	)	$	(18,750,824	)	$	854,896		$	(4,161,013	)		-	$	0		13,485,128	$	13,484	$	14,333,285			(415,328	)	$	(611,854	)	$	(18,750,824	)	$	854,896		$	(4,161,013	)
Foreign currency translation adjustment, net		-		0		0		-			0			0			(473,578	)		(473,578	)		-		0		-		0		0			-			0			0			(473,578	)		(473,578	)
Sale of treasury stock to third party		-		0		249,350		65,000			650			0			0			250,000			-		0		-		0		249,350			65,000			650			0			0			250,000
Restriced stock issued to a consultant		1,800,000		1,800		1,187,650														1,189,450
Restricted stock issued to a consultant																							-		0		1,800,000		1,800		1,187,650															1,189,450
Conversion of notes payable into shares of common stock		781,819		782		2,563,582		-			0			0			0			2,564,364			-		0		781,819		782		2,563,582			-			0			0			0			2,564,364
Net loss		-		0		0		-			0			(2,173,903	)		0			(2,173,903	)		-		0		-		0		0			-			0			(2,173,903	)		0			(2,173,903	)
Balance at March 31, 2021		16,066,947	$	16,066	$	18,333,867		(350,328	)	$	(611,204	)	$	(20,924,727	)	$	381,318		$	(2,804,680	)		-	$	0		16,066,947	$	16,066	$	18,333,867			(350,328	)	$	(611,204	)	$	(20,924,727	)	$	381,318		$	(2,804,680	)

																																										Accumulated
																						Preferred Stock				Common Stock				Additional			Treasury Stock									Other			Total
																						No. of Shares		Value		No. of Shares		Value		Paid-in Capital			No. of Shares			Value			Accumulated Deficit			Comprehensive Loss			Stockholders' Equity

Balance at January 1, 2022																							-	$	0		17,544,509	$	17,544	$	39,675,753			(387,424	)	$	(816,707	)	$	(34,345,506	)	$	(151,621	)	$	4,379,463
Foreign currency translation adjustment, net		-		0		0		-			0			0			284			284			-		0		-		0		0			-			0			0			(405,229	)		(405,229	)
Conversion of related party debt		500,000		500		2,999,500		-			0			0			0			3,000,000
Forgiveness of related party debt		-		-		600,000		-			-			-			-			600,000
Restriced stock issued to a consultant		-		-		1,968,000		-			-			0			0			1,968,000
Net loss		-		-		-		-			-			(2,379,056	)		-			(2,379,056	)
Balance at June 30, 2021		16,566,947		16,566		23,901,367		(350,328	)		(611,204	)		(23,303,783	)		381,602			384,548

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Issuance of Series A preferred stock, net of issuance costs of $547,700																							6,000		5,452,300		-		0		0			-			0			0			0			0
Conversion of notes payable into shares of common stock																							-		0		238,000		238		973,182			-			0			0			0			973,420
Cashless exercise of warrants																							-		0		829,471		829		(829	)		-			0			0			0			0
Net income																							-		0		-		0		0			-			0			203,347			0			203,347
Balance at March 31, 2022																							6,000	$	5,452,300		18,611,980	$	18,611	$	40,648,106		$	(387,424	)	$	(816,707	)	$	(34,142,159	)	$	(556,850	)	$	5,151,001

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

The terms “COSM,” “we,” “the Company,” and “us” as used in this report refer to Cosmos Holdings, Inc. The accompanying unaudited condensed consolidated balance sheet as of ~~June 30, 2021~~March 31, 2022 and unaudited condensed consolidated statements of operations and comprehensive income for the three ~~and six~~ months ended ~~June 30, 2021~~March 31, 2022 have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management of COSM, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three ~~and six~~ months ended ~~June 30, 2021,~~March 31, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2021,~~2022, or any other period. These unaudited consolidated financial statements and notes should be read in conjunction with the financial statements for ~~each of~~ the ~~two years~~year ended December 31, ~~2020 and 2019,~~2021, included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021 (“Form 10-K”). The accompanying condensed consolidated balance sheet as of December 31, ~~2020~~2021 has been derived from the audited financial statements filed in our Form 10-K and is included for comparison purposes in the accompanying balance sheet.

~~Cosmos Holdings Inc. (“us”, “we”, or the “Company”)~~The Company is a ~~multinational~~publicly traded international pharmaceutical company. The Company imports, exports and distributes pharmaceutical products of brand-name and generic pharmaceuticals, over-the-counter (OTC) medicines, and a variety of dietary and vitamin supplements through its established network. Currently, the Company operates its business through its three wholly-owned subsidiaries: (i) SkyPharm, headquartered in Thessaloniki, Greece; (ii) Decahedron Ltd., head-quartered in Harlow, United Kingdom; and (iii) Cosmofarm, headquartered in Athens, Greece. Cosmofarm was acquired in 2018 and we believe this expansion has increased our sales and profit margins as we vertically integrate our business model. The Company also has ancompany with extensive and established distribution ~~direct and indirect~~ network ~~within the European Union (EU).~~

~~The Company’s cross-border pharmaceutical business serves wholesale pharmaceutical distributors and independent retail pharmacies~~ across the EU through its subsidiaries, Decahedron (UK), SkyPharm (Greece) and Cosmofarm (Greece). We are a ~~network~~diversified and vertically integrated broad line pharmaceutical company with our own proprietary line of three strategic distribution centers, as well as an additional warehousing facility. Pharmaceutical manufacturers generally implement variable pricing strategies within the EU market. Identifying and evaluating price spreads between EU member states enables the Company to source brand-name pharmaceuticals from countries where ex-factory prices are comparatively low and export to countries where the same products are priced higher. The Company focuses on leveraging its growing purchasing scale and supplier relationships to secure discounts and provide pharmaceuticals at reduced prices and on continuing to drive organic growth at attractive margins for its cross-border pharmaceutical wholesale business.branded nutraceuticals.

The Company regularly evaluates and undertakes strategic initiatives to expand its distribution reach, improve its profit margins, and strengthen its competitive position. In 2018, the Company entered the vitamins and dietary supplements segment and in the fourth quarter of 2018, the Company posted the first sales of its own brand of nutraceuticals: Sky Premium Life. Through the December 2018 acquisition of Cosmofarm, the Company entered the full-line pharmaceutical wholesale distribution segment. Cosmofarm now serves approximately 1500 independent retail pharmacies and 40 pharmaceutical wholesalers in the greater Athens, Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins, and dietary supplements. We invest in technology to enhance safety, distribution and warehousing efficiency and reliability. Cosmofarm operates two robotic ROWA, a German fully automated warehouse system, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our Athens distribution center.

We make use of analytics and customer feedback from our EU-wide network of wholesale pharmaceutical distributors and independent retail pharmacies to identify and evaluate which nutraceutical product codes to develop to add to our ~~SkyPremium Life~~ ~~portfolio. We intend to continue to bring~~ ~~SkyPremium Life~~ products to market primarily through our existing network of over 160 pharmaceutical wholesale clients and vendors and approximately 370 independent retail pharmacies in the EU. There is growing demand for vitamins and food supplements and we are committed to developing quality products and creating enhanced customer value.

We are also closely monitoring the legal framework for prescription and non-prescription derivatives of cannabis products as it develops in Europe. As the legal framework and processes are developed and implemented in each respective EU country, we intend to utilize our existing network to distribute both prescription and non-prescription derivatives of cannabis products to our current customer base. We currently intend to only distribute prescription and non-prescription derivatives of cannabis products to approved EU countries and not in the US.

We regularly evaluate acquisition targets that would allow us to expand our distribution reach and/or vertically integrate into the supply chain of the products that we currently distribute. We believe that the demand for reasonably priced medicines, delivered on time and in the highest quality is set to increase in the years to come, as the population’s life expectancy increases. With our product portfolio of patented and non-patented medicines, we contribute to the optimization of efficient medicinal care, and thereby lowering cost for health insurance funds, companies, and patients. We also believe that the demand for non-prescription wellness products such as food and dietary supplements will continue to increase as individuals are increasingly supplementing their nutritional intake.

We believe the EU pharmaceutical import/export market will continue to grow. We continue to encounter competition in the market as we grow. The competition comes in the form of level of service, reliability, and product quality. On the procurement side, we continue to expand our vendor base. In order to minimize business risks, we diversify our sources of supply. We maintain our high-quality standards by carefully selecting and qualifying our suppliers, as well as actively ensuring that our suppliers meet our standard of quality control on an ongoing basis.

On July 22, 2015, the Hellenic Ministry of Health and more specifically the National Organization for Medicines granted SkyPharm a license for the wholesale of pharmaceutical products for human use. The license is valid for a period of five years and pursuant to the EU directive of (2013/C343/01). Pursuant to the EU directive of (2013/C 343/01), the Company is subject to fulfill the Guidelines of the Good Distribution Practices of medical products for human use. The Company submitted its application for renewal one month before the license expiration to the Hellenic Republic National Organization, but according to the EMA (eudragmdp.ema.europa.eu/inspections/view/wda/WDAHomePage.xhtml): “Due to the restrictions caused by COVID-19, the period of validity of MIA’s, WDA’s, GMP and GDP certificates is automatically extended until the end of 2021. On-site inspections will resume as soon as there is a consensus that the period of the public health crisis has passed. The clarifying remark section of individual MIA’s, WDA’s, GMP and GDP certificates will indicate any exceptions. Competent authorities reserve the right to inspect a manufacturing site should the need arise.” ~~Therefore, the Company is eligible to continue its operations until at least the end of 2021and expects to receive a temporary license by the end of 2021.~~

Decahedron received its Wholesale Distribution Authorization for human use on November 7, 2013, from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in accordance with Regulation 18 of the Human Medicines Regulations 2012 (SI 2012/1916) and it is subject to the provision of those Regulations and the Medicines Act 1971. This license will continue to remain in force from the date of issue by the Licensing Authority unless cancelled, suspended, revoked or varied as to the period of its validity or relinquished by the authorization holder.

Our subsidiaries are ISO 9001 certified for a management system for the trade and distribution of pharmaceuticals. As part of the certification process by the International Organization for Standardization, we need to be compliant with the General Data Protection Regulation (GDPR) adopted by the European Union. GDPR applies to the processing of personal data of persons in the EU by a controller or processor neither of which apply to our operations.

~~Cosmos Holdings, Inc.~~ was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, ~~2009. On~~2009, and on November 14, 2013, we changed our name to Cosmos Holdings, Inc.

On Through its acquisition of Amplerissimo Ltd, on September 27, 2013, the Company changed its principal activities into trading of products, providing representation, and provision of consulting services to various sectors. On August 1, 2014, the Company formed SkyPharm S.A., a Greek Company (“SkyPharm”), a subsidiary that focuses on the trading, sourcing and export of nutraceutical products. In February 2017, the Company acquired ~~one hundred (100%) percent of the outstanding common stock of Amplerissimo~~Decahedron Ltd., a ~~company incorporated in Cyprus~~UK Company (“~~Amplerissimo”~~Decahedron”), which ~~became~~is a ~~wholly-owned subsidiary~~fully licensed wholesaler of pharmaceutical products, and its primary activity is the ~~Company.~~distribution, import and export of pharmaceuticals.

On November 21, 2017, the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the consolidated financial statements.

On December 19, 2018, the Company completed the purchase of all of the capital stock of Cosmofarm Ltd. ~~(“Cosmofarm”)~~, a pharmaceutical wholesaler based in Athens, Greece. The principal of the selling shareholder is Panagiotis Kozaris, who remained with Cosmofarm as a director and chief operating officer once it became a wholly owned subsidiary of the Company. Grigorios Siokas, the Company’s CEO, became the new CEO of Cosmofarm. Mr. Kozaris had no prior relationship to the Company other than as an independent shareholder. The purchase price payable is €200,000 evidenced by a promissory note.

The Company’s condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. ~~GAAP,~~GAAP”), which contemplates the continuation of the Company as a going concern. For the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, the Company had revenue of ~~$26,466,001,~~$13,071,800, net ~~loss~~income of ~~$4,552,959~~$203,347 and net cash used in operations of ~~$2,519,394.~~$2,337,276. Additionally, as of ~~June 30, 2021,~~March 31, 2022, the Company had working capital of ~~$10,417,725,~~$11,831,133, an accumulated deficit of ~~$23,303,783,~~$34,142,159, and stockholders’ equity of ~~$384,548.~~$5,151,001. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of this filing.

The Company has undergone strategic review processes to help find a definitive solution to the Company’s accumulated deficit constraints. Options under consideration in the strategic review process include, but are not limited to, securing new debt, exchange debt to equity, restructuring current debt facilities from short term to long term and taking the proper actions for new fund raising.

The condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.

The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund its operations. If the Company is unable to obtain adequate capital, it could be forced to ~~cease~~curtail development of operations.

In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations, the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through increased sales of product and by ~~sale of~~ equity and/or ~~debt.~~debt financing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations.

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.

Our condensed consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated.

The preparation of the condensed consolidated financial statements in conformity with ~~generally accepted accounting principles~~U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of ~~August 16, 2021,~~ the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur, and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of ~~June 30, 2021,~~March 31, 2022, and December 31, ~~2020,~~2021, there were no cash equivalents.

The Company maintains bank accounts in the United States denominated in U.S. Dollars and in Greece and in Bulgaria all of them denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling).

Certain reclassifications have been made in the Company’s financial statements of the prior period to conform to the current year presentation. As of December 31, 2021, $7,393 in accumulated depreciation has been reclassified from property and equipment to accumulated amortization of goodwill and intangible assets and $4,772 was reclassified from prepaid expenses and other current assets to marketable securities on the unaudited condensed consolidated balance sheet. For the three ~~and six~~ months ended ~~June 30, 2020, $380,326 and $434,056, respectively, in sales and marketing expenses were~~March 31, 2021, $531,556 was reclassified from general and administrative ~~expenses.~~expenses to salaries and wages on the unaudited condensed consolidated statements of operations and comprehensive income. Additionally, for the ~~six~~three months ended ~~June 30, 2020, $260,347~~March 31, 2021, $1,333 was reclassified from ~~accounts payable and accrued expenses~~customer deposits to ~~accrued interest~~other current liabilities on the ~~Statement~~unaudited condensed consolidated statement of ~~Cash Flows.~~cash flows. These reclassifications have no impact on previously reported net income.

Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables’ portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. ~~As of June 30, 2021,~~At March 31, 2022 and December 31, ~~2020,~~2021, the Company’s allowance for doubtful accounts was ~~$693,485~~$1,668,893 and ~~$715,845,~~$1,702,743, respectively.

The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. The net VAT receivable is recorded in prepaid expense and other current assets on the condensed consolidated balance sheets.

~~June 30,~~ As of March 31, 2022 and December 31, 2021, the Company had a VAT net payable balance of $376,656 and $400,616 respectively, recorded in the condensed consolidated balance sheet as accounts payable and accrued expenses.

Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment.

The Company writes down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met.

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows:

Depreciation expense was ~~$78,341~~$84,884 and ~~$70,739~~$71,471 for the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020, respectively and $149,812 and $124,251 for the six months ended June 30, 2021 and 2020,~~ respectively.

In accordance with ASC 360-10, ~~long-lived assets,~~Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.

The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit.

On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill.

~~On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill.~~

Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for ~~an import/export~~its pharmaceuticals and nutraceuticals products license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of ~~June 30, 2021,~~March 31, 2022, no revision to the remaining amortization period of the intangible assets was made.

Amortization expense was ~~$8,249~~$8,158 and ~~$8,249~~$8,158 for the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020, respectively and $16,407 and $16,497 for the six months ended June 30, 2021 and 2020,~~ respectively.

For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company will record its share in the earnings of the investee and will include it within the condensed consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value.

Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for use in current operations are reported as a component of current assets in the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment.

As of ~~June 30, 2021,~~March 31, 2022, investments consisted of 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp ~~40,000 shares which traded at a closing price of $5.30 per share, or value of $211,368 of Diversa S.A.~~ and 16,666 shares which traded at a closing price of ~~$0.28~~$0.41 per share or value of ~~$4,739~~$6,822 of National Bank of Greece. Additionally, the Company has ~~$4,623~~$5,729 in equity securities of Pancreta Bank, which are ~~not publicly traded and recorded at cost.~~revalued annually. See Note 3, for additional investments in equity securities.

The Company applies ~~FASB~~ ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

The following tables presents assets that are measured and recognized at fair value as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, on a recurring basis:

	June 30, 2021						Total Carrying		March 31, 2022						Total Carrying
	Level 1		Level 2		Level 3		Value		Level 1		Level 2		Level 3		Value
Marketable securities – ICC International Cannabis Corp.	$	0		0		0	$	0	$	-	$	-		-	$	-
Marketable securities – Divsersa S.A.		211,368		0		0		211,368
Marketable securities – National Bank of Greece		4,739		0		0		4,739		6,822		-		-		6,822
Equity securities – Pancreta Bank										-		5,729		-		5,729
	$	216,107					$	216,107	$	6,822	$	5,729			$	12,551

	December 31, 2020						Total Carrying		December 31, 2021						Total Carrying
	Level 1		Level 2		Level 3		Value		Level 1		Level 2		Level 3		Value
Marketable securities – ICC International Cannabis Corp.	$	0		0		0	$	0	$	-	$	-		-	$	-
Marketable securities – Divsersa S.A.		218,183		0		0		218,183
Marketable securities – National Bank of Greece		4,609		0		0		4,609		6,696		-		-		6,696
Equity securities – Pancreta Bank										-		4,772		-		4,772
	$	222,792					$	222,792	$	6,696	$	4,772			$	11,468

In addition, FASB ASC 825-10-25, Fair Value Option, (“ASC 825-10-25”), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.

Derivative financial instruments are recorded in the accompanying condensed consolidated balance sheets at fair value in accordance with ASC 815. When the Company enters into a financial instrument such as a debt or equity agreement (the “host contract”), the Company assesses whether the economic characteristics of any embedded features are clearly and closely related to the primary economic characteristics of the remainder of the host contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the host contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument, then the embedded feature is bifurcated from the host contract and accounted for as a derivative instrument. The estimated fair value of the derivative feature is recorded in the accompanying consolidated balance sheets separately from the carrying value of the host contract. Subsequent changes in the estimated fair value of derivatives are recorded as a gain or loss in the Company’s consolidated statements of operations.

The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company’s ~~products; the~~products. The Company records these receipts as customer advances until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer ~~and deposits~~advances balance and credit the Company’s revenues.

In accordance with ASC 606, Revenue from Contracts with Customers, the Company uses a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon transfer of the product to the customer.

The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (“ASC 718”) and Staff Accounting Bulletin No. 107 (“SAB 107”) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.

The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, “Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.”

Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and amounts included in the accompanying condensed statements of operations and comprehensive income (loss) are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ deficit until the entity is sold or substantially liquidated.

Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in ~~net earnings.~~comprehensive income (loss).

The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 19% in United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership.

We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At ~~June 30, 2021~~March31, 2022 the Company has maintained a valuation allowance against all net deferred tax assets in each jurisdiction in which it is subject to income tax.

Notes to ~~the application of complex income tax regulations to determine income tax liabilities in several jurisdictions.~~ Unaudited Condensed Consolidated Financial Statements

The Company uses a “more likely than not” criterion for recognizing the income tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. The Company has evaluated the impact of these positions and due to the fact that the ~~fiscal years 2013 - 2014 are unaudited~~Company undergoes an annual certified audit each year in lieu of an audit by the Greek tax authorities, ~~a potential tax liability~~the Company has not ~~been identified because there is a limitation on periods~~taken any tax positions that ~~the Tax authorities can audit retrospectively 5 years prior to the current fiscal year. Therefore, no prospective tax audit from tax authorities may arise.~~warrant accrual under ASC-740-10.

Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee’s work experience and renumeration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. The amount of the liability as of June 30, 2021 and December 31, 2020, was $102,901 and $107,167 respectively, and has been recorded as a long-term liability within the condensed consolidated balance sheets.

Basic income per share is calculated by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding.

	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended March 31,
	2021		2020		2021		2020		2022		2021
Weighted average number of common shares outstanding Basic		16,105,409		13,225,387		15,572,773		13,225,387
Weighted average number of common shares outstanding-Basic										17,755,516		15,034,219
Potentially dilutive common stock equivalents		-		28,729		-		29,566		-		-
Weighted average number of common and equivalent shares outstanding - Diluted		16,105,409		13,254,116		15,572,773		13,254,953		17,755,516		15,034,219

Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented.

On October 2021, the Financial Accounting Standards Board (“FASB”) issued accounting standards update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The new guidance creates an exception to the general recognition and measurement principles of ASC 805, Business Combinations. The new guidance should be applied prospectively and is effective for all public business entities for fiscal years beginning after December 15, 2022 and include interim periods. The guidance is effective for all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the effects of the adoption of ASU No. 2021-08 on its consolidated financial statements.

In ~~August 2020,~~May 2021, the FASB issued ASU ~~No. 2020-06 (“ASU 2020-06”)~~2021-04—Earnings Per Share (Topic 260), Debt—~~Debt with Conversion~~ Modifications and ~~Other Options~~Extinguishments (Subtopic ~~470-20)~~470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for ~~Convertible Instruments~~Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, to clarify and ~~Contracts~~reduce diversity in an ~~Entity’s Own Equity.” ASU 2020-06 will simplify the~~issuer’s accounting for ~~convertible instruments by reducing the number~~modifications or exchanges of ~~accounting models~~freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU are effective for ~~convertible debt instruments~~public and ~~convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared~~nonpublic entities for fiscal years beginning after December 15, 2021, and interim periods with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company.fiscal years beginning after December 15, 2021. Early adoption is permitted, ~~but no earlier than January 1, 2021,~~ including adoption in an interim ~~periods within that year. Management~~period. The Company is currently evaluating the ~~effect~~effects of the adoption of ASU ~~2020-06~~No. 2021-04 on ~~the~~its consolidated financial statements.

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.

On March 19, 2018, the Company entered into a Distribution and Equity Acquisition Agreement (the “Distribution and Equity Acquisition Agreement”) with Marathon Global Inc. (“Marathon”), a company incorporated in the Province of Ontario, Canada. Marathon was formed to be a global supplier of cannabis, cannabidiol (CBD) and/or any cannabis extract products, extracts, ancillaries and derivatives (collectively, the “Products”). The Company was appointed the exclusive distributor of the Products initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. The Company has no present intention to distribute any Products under this Agreement in the United States or otherwise participate in cannabis operations in the United States. The Company intends to await further clarification from the U.S. Government on cannabis regulation prior to determining whether to enter the domestic market.

The Distribution and Equity Acquisition Agreement is to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five (5) years of the agreement. The transaction closed on May 22, 2018 after the due diligence period, following which the Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. The Company was also given the right to nominate one director to the Marathon board of directors.

Since Marathon was a newly formed entity with no assets and no activity, the Company attributed no value to the 5 million shares in Marathon which was received as consideration for the distribution services. As described below, the Company exchanged the Marathon shares in May and July 2018.

On May 17, 2018, the Company entered into a Share Exchange Agreement (the “SEA”) with Marathon, ICC International Cannabis Corp (“ICC”) formerly known as Kaneh Bosm Biotechnology Inc. (“KBB”) and certain other sellers of Marathon capital stock. Under the SEA, the Company transferred 2.5 million shares in Marathon to ICC, a corporation incorporated under the laws of the Province of British Columbia and a public reporting issuer on the Canadian Securities Exchange, in exchange for 5 million shares of ICC. The Company accounted for the exchange at fair value and recognized a gain on exchange of its investment in Marathon of $1,953,000 in the year ended December 31, 2018.

On July 16, 2018, the Company completed a Share Exchange Agreement (the “New SEA”) with Marathon, ICC, and certain other sellers of Marathon capital stock whereby the Company transferred its remaining one-half interest (2.5 million shares) in Marathon to KBB for an additional 5 million shares of ICC. The Company accounted for the exchange at fair value and recognized a gain on exchange of its investment in Marathon of $2,092,200 in the year ended December 31, 2018. The ten million shares of ICC owned by the Company constituted approximately 7% of the 141,219,108 shares of capital stock of KBB then issued and outstanding. The Company does not have the ability to exercise significant influence over ICC.

The Company determined the fair value of both exchanges based on an actively quoted stock price of ICC received in exchange for the Marathon shares. The Company continues to fair value its investment in ICC with changes recognized in earnings each period and was recorded as an unrealized gain on exchange of investment during the six months ended ~~June 30, 2021~~March 31, 2022 of $0. The value of the investments as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, was $0 and $0, respectively.

Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services, the Company would receive variable consideration in future for its services under the Distribution and Equity Acquisition Agreement, if certain milestones are achieved. Refer to Note 1112 for the accounting associated with the cash of CAD $2 million received upfront. Variable consideration to be received in the future upon achieving the gross sales milestones described above, is constrained as the Company estimates that it is probable that a significant reversal of revenue could occur. In assessing the constraint, the Company considered its limited experience with the Products, new geographic markets and similar transactions, which affect the Company’s ability to estimate the likelihood of a probable revenue reversal. Therefore, no revenue has been recognized for the period ended ~~June 30, 2021.~~March 31, 2022. The Company will continue to reassess variable consideration at each reporting period and update the transaction price when it becomes probable that a significant revenue reversal would not occur.

As of ~~June 30, 2021,~~March 31, 2022, in addition to the 3,000,000 ICC shares valued at $0, as noted above, marketable securities also consisted of the following: ~~40,000 shares which traded at a closing price of $5.30 per share, or value of $211,368 of Diversa S.A. and~~ 16,666 shares which traded at a closing price of ~~$0.28~~$0.41 per share or value of ~~$4,739~~$6,822 of National Bank of Greece. Additionally, the Company has $5,729 in equity securities of Pancreta Bank, which are revalued annually. The Company recorded a net unrealized gain on the fair value of these investments of ~~$279~~$1,678 during the ~~six~~three months ended ~~June 30, 2021.~~March 31, 2022.

In ~~June~~September 2019, the Company entered into an agreement with an unaffiliated third party to incorporate CosmoFarmacy L.P. for the purpose of providing strategic management consulting services and the retail trade of pharmaceutical products, and OTC to pharmacies. CosmoFarmacy was incorporated with a 30-year term through May 31, 2049. The unaffiliated third party is the general partner (the “GP”) of the limited partnership and is responsible for management and decision-making associated with CosmoFarmacy. The initial share capital was set to EUR 150,000 which was later increased to EUR 500,000. The GP contributed the pharmacy license (the “License”) valued at EUR 350,000 (30-year term) to operate the business of CosmoFarmacy in exchange for a 70% equity ownership. The Company is a limited partner and contributed cash of EUR 150,000 for the remaining 30% equity ownership. CosmoFarmacy is not publicly traded and the Company’s investment has been recorded using the equity method of accounting. The value of the investment as of ~~June 30,~~March 31, 2022 and December 31, 2021 was ~~$177,720~~$166,395 and $169,770, respectively, and is included in “Other assets” onin the ~~Company’s~~accompanying condensed consolidated balance sheet.

	June 30, 2021			December 31, 2020			March 31, 2022			December 31, 2021
Leasehold improvements	$	543,451		$	560,711		$	508,920		$	519,278
Vehicles		101,183			105,057			94,735			96,657
Furniture, fixtures and equipment		1,597,143			1,632,654			2,027,470			2,065,100
Computers and software		142,216			149,005			140,452			141,490
		2,383,993			2,447,427			2,771,577			2,822,525
Less: Accumulated depreciation and amortization		(805,952	)		(690,214	)		(993,688	)		(934,473	)
Total	$	1,578,041		$	1,757,213		$	1,777,889		$	1,888,052

	June 30, 2021			December 31, 2020			March 31, 2022			December 31, 2021
License	$	50,000		$	50,000		$	339,860		$	345,739
Trade name / mark		36,997			36,997			36,997			36,997
Customer base		176,793			176,793			176,793			176,793
		263,790			263,790			553,650			559,529
Less: Accumulated amortization		(99,388	)		(82,981	)		(138,717	)		(123,459	)
Subtotal		164,402			180,809			414,933			436,070
Goodwill		49,697			49,697			49,697			49,697
Total	$	214,099		$	230,506		$	464,630		$	485,767

On October 30, 2021, the Company entered into an agreement for a ten-year loan with a third-party to memorialize €4,284,521 ($4,849,221) in prepayments the Company had made. Interest is calculated at a rate of 5.5% per annum on a 360-day basis. Under the terms of the agreement, the Company is to receive 120 equal payments over the term of the loan. As of December 31, 2021, the Company had a short-term receivable balance of $377,590 and a long-term receivable balance of $4,410,689 under this loan. During the three months ended March 31, 2022, the Company received €81,696 ($90,626) in principal payments such that as of March 31, 2022, the Company had a short-term receivable balance of $375,195 and a long-term receivable balance of $4,227,268 under this loan.

The Company is incorporated in the United States of America and is subject to United States federal taxation. No provisions for income taxes have been made as the Company had no U.S. taxable income for the three ~~and six~~ months ended ~~June 30, 2021~~March 31, 2022 and ~~2020.~~2021.

The Company’s Greece subsidiaries are governed by the income tax laws of Greece. The corporate tax rate in Greece is 22% on income reported in the statutory financial statements after appropriate tax adjustments.

The Company’s United Kingdom subsidiaries are governed by the income tax laws of the United Kingdom. The corporate tax rate in the United Kingdom is 19% on income reported in the statutory financial statements after appropriate tax adjustments.

As of ~~June 30,~~March, 31 2022 and 2021, ~~and 2020,~~ the Company’s effective tax rate differs from the USU.S. federal statutory tax rate primarily due to a valuation allowance recorded against net deferred tax assets in in the United States.

We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. As of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, the Company has maintained a valuation allowance against all net deferred tax assets in the United States only. Foreign valuation allowances ~~had been~~were reversed ~~as of~~on December 31, 2020.

~~As of June 30,~~For the three months ended March 31, 2022 and 2021, ~~and December 31, 2020,~~ the Company has recorded a tax benefit ~~for tax recorded~~(expense) in any jurisdiction where it is subject to income tax, in the amount of ~~$286,329~~($65,667) and ~~$178,430,~~$315,912, respectively, ~~which is included in Deferred tax assets~~ on the condensed consolidated ~~balance sheets.~~statement of operations and comprehensive income (loss).

The Company is authorized to issue 100 million shares of preferred stock, of which ~~may be issued~~6,000,000 are designated as Series A convertible preferred stock. The preferred stock has liquidation preference over the common stock and are non-voting. As of March 31, 2022 and December 31, 2021, 6,000 and 0, respectively, preferred shares have been issued.

On and effective October 4, 2021, the Company amended and restated its articles of incorporation (the Amended and Restated Articles”) and filed a certificate of designation (the “COD”) for its Series A Preferred Stock (the “Series A Preferred Stock”) with the State of Nevada.

The Amended and Restated Articles allow the Company’s Board of Directors the authority to authorize the issuance of preferred stock from time to time in one or more classes or series ~~authorized~~ by ~~the Board of Directors. As of June 30, 2021, no preferred shares have been issued.~~

The Series A Preferred Stock is convertible into the Company’s Common Stock as determined by dividing the number of shares of Series A Preferred Stock to be converted by the lower of (i) $4.00 or (ii) 80% of the average volume weighted average price for the Company’s Common Stock for the five (5) days prior to the date of Uplisting, subject to a floor of $3.00 (the “Conversion Price”).

The holders of the Series A Preferred Stock are not entitled to dividends or to receive distributions in the event of liquidation, dissolution or winding up of the Company, ~~is authorized~~either voluntary or involuntary.

On February 28, 2022, the Company entered into a securities purchase agreement, or the Purchase Agreement, with certain investors and an insider for a private placement of the Company’s securities (the “Private Placement”).

The Private Placement consisted of the sale of 6,000 shares of the Company’s Series A Convertible Preferred Stock, or the Series A Shares, at a price of $1.000 per share, and 2,000,000 warrants to ~~issue 300 million~~purchase shares of common ~~stock.~~stock, or the Warrants, for aggregate gross proceeds of approximately $6 million. The Warrants are exercisable to purchase shares of common stock at $3.30 per share, or 110% of the Series A Shares initial conversion price and will expire five and one-half years following the initial exercise date of the Warrants. The Company determined that the 2,000,000 warrants are additional value being distributed to the preferred stockholders and presented the warrants’ fair value of $5,788,493 as a deemed dividend in the unaudited condensed consolidated statements of operations and comprehensive income (loss). The warrants were valued using the Black-Scholes option pricing model with the following terms: a) exercise price of $3.30, b) common stock fair value of $3.42, c) volatility of 118%, d) discount rate of $1.71%, and e) dividend rate of 0%.

The closing of the Private Placement occurred on February 28, 2022. As a condition to the closing of ~~June 30, 2021~~the sale, the Company’s common stock received conditional approval for listing and ~~December 31, 2020,~~trading on the Nasdaq Capital Market and commenced trading on February 28, 2022, under the trading symbol, COSM. Concurrent with the issuance of the Series A Shares, the Company ~~had 16,566,947 and 13,485,128~~executed a registration rights agreement (the “Registration Rights Agreement”) to register the resale of the shares of ~~our~~ common stock issuable upon conversion of the Series A Shares and the shares of common stock issuable upon exercise of the warrants issued in connection with the Series A Shares. The Company is required to file its initial registration statement within 45 days following February 28, 2022. The Effectiveness Date is required to be 60 days after February 28, 2022, or 75 days following the SEC’s full review, and ~~16,216,619~~any additional registration statements that may be required are to be filed within 20 days following the date required by the SEC. If the Company fails to timely file its initial registration statement, or any additional registration statement, or otherwise comply with the requirements of the Registration Rights Agreement, the Company shall pay each holder 2% of the subscription amount in cash until cured, with an additional penalty of 18% if the cash payment is not made within seven days of the cash payable date.

The Series A Shares rank senior to all of the Company’s Common Stock and ~~13,069,800~~any other equity securities that the Company may issue in the future with respect to payment of dividends and distribution of assets upon liquidation, dissolution or winding up. While the Series A Shares are outstanding, the Company may not amend, alter or change adversely the powers, preferences or rights given to the Series A Shares, create, or authorize the creation of, any additional class or series of capital stock of the Company (or any security convertible into or exercisable for any class or series of capital stock of the Company), including any class or series of capital stock of the Company that ranks superior to or in parity with the Series A Shares, alter, amend, modify, or repeal its Articles of Incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Shares, increase or decrease the number of authorized shares of Series A Shares, any agreement, commitment or transaction that would result in a Change of Control, any sale or disposition of any material assets outside of the ordinary course of business of the Company, any material change in the principal business of the Company, including the entry into any new line of business or exit of any current line of business, and circumvent a right or preference of the Series A Shares. Any holder of the Series A Shares shall have the right by written election to the Company to convert all or any portion of the outstanding ~~respectively.~~Series A Preferred Shares. Immediately upon effectiveness of a registration statement registering for resale all of the Registrable Securities (as defined in the Registration Rights Agreement), all outstanding Series A Preferred Shares shall automatically convert into Common Stock, subject to certain beneficial ownership limitations.

~~Purchase~~The Series A Shares are recorded as mezzanine equity in accordance with ASC 480 at its initial net carrying value in the amount of ~~Treasury~~$5,452,300. The Series A Shares are recorded as mezzanine equity in accordance with ASC 480 because the Company may be obligated to issue a variable number of shares at a fixed price known at inception and there is no maximum number of shares that could potentially be issued upon conversion. In this instance, cash settlement would be presumed and the Series A Shares are classified as mezzanine equity in accordance with ASC 480-10-S99. Immediately upon effectiveness of the registration statement registering for resale of all the common stock issuable under the Series A Shares, all outstanding Series A Shares shall automatically convert into common stock.

The Company ~~entered into a Stock Purchase Agreement (the “July SPA”) with a stockholder. The July SPA provides for the Company’s purchase of 10,000~~is authorized to issue 300 million shares of ~~the Company’s~~ common ~~stock at $4.00 per share or an aggregate of $40,000.~~stock. As of March 31, 2022 and December 31, ~~2020, the Company made $40,000 in payments.~~

On August 31, 2020, the Company entered into two Stock Purchase Agreements (the “August SPAs”) with a stockholder. The August SPAs provide for the Company’s purchase of an aggregate total of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. As of December 31, 2020, the Company made $40,000 in payments.

On September 30, 2020, the Company entered into a Stock Purchase Agreement (the “July SPA”) with a stockholder. The July SPA provides for the Company’s purchase of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. As of December 31, 2020, the Company made $40,000 in payments.

On October 31, 2020, the Company entered into a Stock Purchase Agreement (the “July SPA”) with a stockholder. The July SPA provides for the Company’s purchase of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. As of December 31, 2020, the Company made $40,000 in payments.

On November 30, 2020, the Company entered into a Stock Purchase Agreement (the “July SPA”) with a stockholder. The July SPA provides for the Company’s purchase of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. As of December 31, 2020, the Company made $40,000 in payments.

~~On February 5,~~ 2021, the Company ~~entered into a Stock Purchase Agreement (the “February SPA”) with an unaffiliated third-party. The February SPA provides for the Company’s to sell 65,000~~had 18,611,980 and 17,544,509 shares of ~~the Company’s~~our common stock ~~held in treasury at $3.85 per share or a total of $250,000.~~issued, respectively, and 18,224,556 and 17,157,085 shares outstanding, respectively.

The Company entered into a Consulting Agreement (the “Agreement”) effective as of February 5, 2021, with a non-affiliated consultant (the “Consultant”). The Company engaged the Consultant to perform consulting services relating to Company management, debt structure, business plans and business development in connection with any capitalization transactions involving the Company and any newly created or existing entities. The Agreement is for a term of nine (9) months with an initial term of ninety (90) days (the “Initial Term”). The Agreement is terminable by the Company for any reason upon written notice at any time after the Initial Term.

The Company agreed to pay Consultant and its assignees an aggregate of 1,800,000 restricted shares of Common Stock, earned at the rate of 200,000 shares per month, which shall be issued and fully paid for in consideration of the Consultant’s considerable expertise and experience and its commitment to work for the Company. However, in the event the Agreement is terminated for any reason after the Initial Term, the shares are subject to a claw back for any months remaining after the Termination Date. The ~~Consultant retained 800,000 of the 1,800,000~~ shares and agreed with an assignee and the Company that 1,600,000 of the 1,800,000 shares shall be held in book entry for six (6) months from the date of this Agreement, subject to the above claw back. The shareswere valued on the date of the agreement at $3.28 per share or $5,904,000, which ~~will~~was be amortized over the term of the agreement. As of ~~June 30,~~March 31, 2022 and 2021, the Company has ~~recorded $3,157,451 in stock-based compensation~~expensed $0 and $1,189,451 under the agreement.

As of February 5, 2021, The Company entered into an Amended and Restated Debt Exchange Agreement (the “Agreement”) with the “Lender that provided for the ~~1,000,000~~issuance by the Company of 781,819 shares ~~earned through~~of common stock (the “Exchange Shares”), at the ~~end~~rate of $3.85 per share, in exchange for an aggregate of $3,010,000 principal amount of existing loans made by the Lender to the Company (See Note 11). The market price at the time this Agreement was negotiated was $3.28 per share and the Company recorded a gain on debt extinguishment of $445,636 during the three months ended March 31, 2021. As of March 31, 2021, the Company recorded $2,564,363 as an equity increase related to the extinguishment of debt.

During the three months ended March 31, 2022, the Company issued 238,000 shares of common stock upon the conversion of $1,190,000 of notes payable. The Company recorded $973,420 as a capital contribution and an increase in equity related to the conversion of the ~~period.~~$1,190,000 reduced by $216,580 recorded as a gain upon extinguishment of debt upon modification. The $216,580 gain upon extinguishment was determined using the fair value of the Company of $4.09 per share at the extinguishment commitment date.

~~On June 23, 2021,~~During the three months ended March 31, 2022, the Company entered into a Debt Exchange Agreement (the “June Debt Exchange Agreement”) to exchange various loans pursuant to which the related party Lender has made (See Note 8), in the aggregate principal amount of $3,000,000 (the “Debt”). The Company agreed to issue the Lenderissued 829,471 shares of common stock upon the cashless exercise of the Company at an exchange rate of $6.00 per share (the “Exchange Shares”) in exchange for the principal amount of Debt of $3,000,000 or 500,000 shares of common stock (exchange rate of $6.00 per share). On June 23, 2021, the fair value of the Company’s shares of common stock was $5.00 per share. For the three and six months ended June 30, 2021, the Company recorded $3,000,000 as a capital contribution and an increase in equity in accordance with ASC 850-10-20 due to the related party relationship and ASC 470-50-40-20 which provides guidance on extinguishments of related party debt. Accordingly, extinguishment transactions between related entities are in essence capital transaction, and no gain is recorded in the consolidated statements of operations for the difference between the fair value of $5.00 per share and the exchange rate of $6.00 per share.2,748,797 warrant shares.

No options warrants or other potentially dilutive securities other than those disclosed above have been issued as of ~~June 30, 2021 and December~~March 31, ~~2020, respectively.~~2022.

On the date of our inception, we issued 2 million shares of our common stock to our three officers and directors which were recorded at no value (offsetting increases and decreases in common stock and additional paid-in capital).

As of ~~June 30, 2021,~~March 31, 2022, the Company has a prepaid balance of ~~$2,917,334~~$4,368,794 and an accounts payable balance of ~~$177,161,~~$220,518, resulting in a net prepaid balance of ~~$2,740,173~~$4,148,276 to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company has a receivable balance of ~~$3,135,184.~~$2,844,572. As of December 31, ~~2020,~~2021, the Company has a prepaid balance of ~~$3,468,653~~$3,263,241 to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company had a receivable balance of ~~$3,468,564.~~$2,901,300 and an accounts payable balance of $565,756

During the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020,~~ the Company purchased a total of ~~$1,091,118~~$687,382 and ~~$644,643~~$589,261 of products from Doc Pharma S.A., respectively. During the three months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~ the Company had ~~$523,712~~$383,688 and ~~$1,107,822, in revenue from Doc Pharma S.A., respectively.~~

During the six months ended June 30, 2021 and 2020, the Company purchased a total of $1,413,924 and $1,315,274, respectively, of products from Doc Pharma S.A. During the six months ended June 30, 2021 and 2020 the Company had $796,917 and $1,469,365,$290,598, in revenue from Doc Pharma S.A., respectively.

On October 10, 2020, the Company entered into a contract manufacturer outsourcing “CMO” agreement with ~~DOC Pharma~~DocPharma whereby ~~DOC~~Doc Pharma is responsible for the development and manufacturing of pharmaceutical products and nutritional supplements according to the Company’s specifications based on strict pharmaceutical standards and ~~GMP (Good Manufacturing Practice)~~good manufacturing practice (“GMP”) protocols as the National Organization for Medicines requires. The Company has the exclusive ownership rights for trading and distribution of its own branded nutritional supplements named “Sky Premium ~~Life” (“SPL”)~~Life^®”. The duration of the agreement is for 5 years however either party may terminate the agreement at any time giving six-months advance notice. ~~DOC~~Doc Pharma is exclusively responsible for supplying the raw materials and packaging required to manufacture the final product. However, they are not responsible for potential delays that may arise, concerning their import. ~~DOC~~Doc Pharma is obliged to store the raw and packaging materials. The delivery of raw and packaging materials should be purchased at least 30 and 25 days, respectively, before the delivery date of the final product. The Manufacturer solely delivers the finished product to the Company. There is a minimum order quantity ~~(MoQ)~~“MoQ” of 1,000 pieces per product code. Both parties have agreed that the Company will deposit 60% of the total cost upon agreement and assignment and 40% of the total cost including VAT charge upon the delivery date. The prices are indicative and are subject to amendments if the cost of the raw material or the production cost change. As of ~~June 30, 2021,~~March 31, 2022, the Company has purchased ~~€505,861~~€ 461,453 ($~~599,344)~~517,566) in inventory related to this agreement.

On May 17, 2021, Doc Pharma and the Company entered into a Research and Development “R&D” agreement whereby Doc Pharma will be responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life^®. These products will be sold in Greece and abroad. The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). In the year ended December 31, 2021, SkyPharm bought 67 licenses at value of €261,300 ($289,860) from Doc Pharma which was the 18.33% of the total cost. The agreement will be terminated on December 31, 2025.

Doc Pharma S.A is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma S.A. in the past.

A summary of the Company’s related party notes payable as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020~~2021 is presented below:

On December 20, 2018, the €1,500,000 ($1,718,400) note payable, originally borrowed pursuant to a Loan Agreement with a third-party lender, dated March 16, 2018, was transferred to Grigorios Siokas. The note bears an interest rate of 4.7% per annum, ~~and~~ matured on March 18, 2019 pursuant to the original ~~agreement.~~agreement and was extended until December 31, 2021. The note is not in default and the maturity date has been extended again until December 31, ~~2021.~~2023. As of December 31, ~~2020,~~2021 the ~~note~~Company had an outstanding ~~principal~~ balance of €400,000 ($~~489,200)~~452,720) and accrued interest of ~~€158,287~~€177,313 ($~~193,585)~~200,683). As of ~~June 30, 2021,~~March 31, 2022, the Company has an outstanding balance of €400,000 ($~~473,920)~~443,720) and accrued interest of ~~€203,017~~€181,948 ($~~240,535)~~201,835).

On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. As of December 31, ~~2020,~~2021, the Company had a principal balance of €10,200 ($~~12,475)~~11,544). A principal balance of €10,200 ($~~12,085)~~11,315) remained as of ~~June 30, 2021.~~March 31, 2022.

The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the ~~six~~three months ended ~~June 30, 2021~~March 31, 2022, the Company recorded a ~~loss~~gain of ~~$15,670.~~$9,229.

A summary of the Company’s related party loans payable during the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, and the year ended December 31, ~~2020~~2021 is presented below:

From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of December 31, 2020, the Company had an outstanding principal balance under these loans of $1,629,246 in loans payable to Grigorios Siokas.

From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of December 31, 2021, the Company ~~entered into a Debt Exchange agreement (“May Debt Exchange”) related~~had an outstanding principal balance under these loans of $1,293,472 in loans payable to ~~a lawsuit from on or about July 25, 2019, whereby Mark Rubenstein, individually and as a shareholder of the Company, brought the action styled~~ ~~Rubenstein v. Siokas, et al.~~~~, Case No. 1:19-cv-06976-KPF (S.D.N.Y.) against~~ Grigorios Siokas for recovery of alleged profits earned under Section 16(b) of the Securities Exchange Act of 1934. Although recovery was sought only from Mr. Siokas, the Company was also named as a nominal defendant. Both the Company and Mr. Siokas vigorously defended the lawsuit. On or about September, 18, 2020, in an effort to avoid the uncertainty of litigation and further legal expense, Mr. Siokas agreed to settle the lawsuit by agreeing to reimburse the Company a total of six hundred thousand ($600,000) dollars, payable as a combination of: (1) Mr. Siokas reimbursing the Company for Plaintiff’s attorneys’ fees, in an amount subsequently determined by the Court to be $120,000 plus $4,137 of litigation costs to be paid in cash, and (2) Mr. Siokas relieving the Company of certain debt owed to him. Mr. Siokas and the Company strongly opposed Plaintiff’s motion for attorneys’ fees. The Company has accrued the Plaintiff’s attorney’s fees and the balance as of June 30, 2021 was $124,137 and is included in accounts payable and accrued expenses on the balance condensed consolidated balance sheet. Pursuant to the terms of the May Debt Exchange the Company forgave $600,000 of the existing loan payable and recorded the forgiveness to additional paid in capital.Siokas.

On June 23, 2021, the Company entered into an exchange agreement (“June Exchange Agreement”) with Mr. Siokas whereby an aggregate total of $3,000,000 of these outstanding loans were converted into 500,000 shares of the Company’s common stock. During the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, the Company borrowed additional proceeds of ~~€1,080,000~~€321,000 ($~~1,281,562)~~356,085), and ~~$1,529,500~~$100,000 and repaid ~~€106,000~~€20,000 ($~~125,589)~~22,186) of these loans. ~~As of June 30, 2021, the Company had an outstanding balance under these loans of $704,403.~~

The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the ~~six~~three months ended ~~June 30, 2021~~March 31, 2022 the Company recorded a ~~loss~~gain of ~~$10,316.~~$23,490.

Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.

A summary of the Company’s lines of credit as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020~~2021 is presented below:

The line of credit with National Bank of Greece is ~~being~~ renewed annually with current interest rates of 6.00%, 4.35% (“COSME 2”) facility) and 4.35% (plus the 6-month Euribor plus any contributions currently in force by law on certain lines of credit), (“COSME 1”) facility).

The maximum borrowing allowed for the 6% line of credit was ~~$2,606,560~~$3,300,168 and ~~$2,690,600~~$2,489,960 as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020, respectively for the 6% line of credit.~~2021, respectively. The outstanding balance of the facility was ~~$2,103,897~~$1,833,394 and ~~$2,411,182~~$2,185,413, as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, respectively.

The maximum borrowing allowed ~~was $1,184,800 and $1,223,000 as of June 30, 2021 and December 31, 2020, respectively,~~ for the 4.35% lines of ~~credit.~~credit, was $1,109,300 and $1,131,800 as of March 31, 2022 and December 31, 2021, respectively. The outstanding balance of the facilities was ~~$989,746~~$1,053,749 and ~~$1,129,368~~$1,079,823 as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, respectively.

The line of credit with Alpha Bank of Greece is renewed annually with a current interest rate of 6.00%. The maximum borrowing allowed was ~~$1,184,800~~$1,109,300 and ~~$1,123,000~~$1,131,800 as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, respectively. The outstanding balance of the facility was ~~$1,019,368~~$927,008 and ~~$1,106,894~~$947,333, as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, respectively.

The Company entered into a line of credit with Pancreta bank on February 23,2021. The line of credit is renewed annually with a current interest rate of 6.10%. The maximum borrowing allowed was $592,400 at June 30, 2021. The outstanding balance was $532,191 as of June 30, 2021.

The Company entered into a line of credit with Pancreta Bank on February 23, 2021. The line of credit is renewed annually with a current interest rate of 6.10%. The maximum borrowing allowed as of March 31, 2022 and December 31, 2021 was $554,650 and $565,900, respectively. The outstanding balance of the facility as of March 31, 2022 and December 31, 2021, was $417,671 and $489,985, respectively.

Interest expense for the three ~~month period ended June 30, 2021 and 2020, was $137,088.11 and $92,747, respectively.~~

~~Interest expense for the six~~ months ended ~~June 30,~~March 31, 2022 and 2021, was $17,175 and ~~2020, was $153,589 and $110,420,~~$16,501, respectively.

Under the agreements, the Company is required to maintain certain financial ratios and covenants. These lines of credit were assumed in the Company’s acquisition of Cosmofarm. ~~During the three and six months ended June 30, 2021~~As of March 31, 2022 and December 31, ~~2020,~~2021, the Company was in compliance with these ratios and covenants.

The above lines of credit are guaranteed and backed by customer receivable checks and they are not considered to be a direct debt obligation for the Company. They are a type of factoring, where the postponed customer checks are assigned by the Company to the bank, in order to be financed at a pre-agreed rate.

On June 23, 2020, the Company’s subsidiary, Cosmofarm, entered into an agreement with the “National Bank of Greece SA” (the “Bank”) to borrow a maximum of €500,000 ($611,500) under a proposed plan which will operate the same as the line of credit above. The proposed plan has a maturity date of sixty (60) months from the date of the first disbursement, which includes a grace period of nine months. The total amount of the initial proceeds were paid in 3 equal monthly installments. The line of credit is interest bearing from the date of receipt and is payable every three (3) months at an interest rate of 2.7%. The outstanding balance was $393,709 and $429,240 at June 30, 2021 and December 31, 2020.

Interest expense for ~~the~~ three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021 was ~~$0.~~$413 and $0, respectively.

A summary of the Company’s convertible debt ~~during the six months ended June 30, 2021~~at March 31, 2022 and ~~the year ended~~ December 31, ~~2020~~2021 is presented below:

	2021			2020			March 31, 2022			December 31, 2021

Beginning balance convertible notes		1,447,000			1,500,000		$	640,000		$	1,447,000
New notes		100,000			540,000			0			625,000
Payments		(362,000	)		(593,000	)		0			(907,000	)
Conversion to common stock								0			(525,000	)
Subtotal notes		1,185,000			1,447,000			640,000			640,000
Debt discount at year end		(418,504	)		(494,973	)		(191,085	)		(258,938	)
Convertible note payable net of discount		766,496			952,027
Convertible note payable, net of discount							$	448,915		$	381,062

All of the convertible debt is classified as short-term within the consolidated balance sheet as it all matures and will be paid back within fiscal year ~~2021.~~

On May 15, 2019, the Company entered into a Securities Purchase Agreement with an institutional investor (the “Buyer”). Upon the closing of this financing, on May 17, 2019, the Company issued for a purchase price of $1,500,000 in principal amount a Senior Convertible Note (the “May 2019 Note”) to the Buyer. The May 2019 Note provided that the Company will repay the principal amount of the May 2019 Note on or before March 15, 2020.

On March 23, 2020, the Company entered into a Forbearance and Amendment Agreement (the “Agreement”) with an institutional investor (the “Buyer”). The Agreement provides that the Buyer will (a) forbear (i) from taking any action with respect to the Existing Default and (ii) from issuing any demand for redemption of the Note on the basis of the Existing Default until the earlier of: (1): (September 16, 2020 (or, if earlier, such date when all amounts outstanding under the Note shall be paid in full or converted into shares of Common Stock in accordance therewith) and (2) the time of any breach by the Company of the Agreement or the occurrence of an Event of Default that is not an Existing Default (the “Forbearance Expiration Date”), (b) during the Forbearance Period waive the prepayment premium to any Company Optional Redemption, and (c) during the Forbearance Period, waive the repayment in full of the Note other than the Required Payments (as defined) prior to September 16, 2020. The Scheduled Required Prepayments are $100,000 upon signing the Agreement and five (5) monthly payments thereafter aggregating $200,000 with all amounts outstanding under the Note due on September 16, 2020. In addition, there are mandatory prepayments in the event the Company completes a Subsequent Placement (as defined) or long-term debt (other than from the Buyer or from officers and directors and advisors of the Company) or factoring and purchase order indebtedness, the Company shall effect a Company Optional Redemption amount equal to 50% of the gross proceeds (less reasonable expenses of counsel and any investment bank) together with all Scheduled Required Payments.

On September 23, 2020, the Company entered into a Second Forbearance and Amendment Agreement (the “Agreement”) with the Buyer. Pursuant to the March 23, 2020, Forbearance and Amendment Agreement. The Note was due to be paid in full on or before September 16, 2020 and was not paid (the “Existing Default”). The Note provides that upon an Event of Default, the Buyer may, among other things, require the Company to redeem all or a portion of the Note at a redemption premium of 120%, multiplied by the product of the conversion rate ($6.00per share) and the then current market price.

The Agreement provides that the Buyer will (a) forbear (i) from taking any action with respect to the Existing Default and (ii) from issuing any demand for redemption of the Note on the basis of the Existing Default until the earlier of: (1): June 16, 2021 (or, if earlier, such date when all amounts outstanding under the Note shall be paid in full or converted into shares of Common Stock in accordance therewith) and (2) the time of any breach by the Company of the Agreement or the occurrence of an Event of Default that is not an Existing Default (the “Forbearance Expiration Date), (b) during the Forbearance Period (as defined) waive the prepayment premium to any Company Optional Redemption (which will result in the 120% redemption premium effectively replaced with 100%), and (c) during the Forbearance Period, waive the repayment in full of the Note other than the Required Payments (as defined) prior to June 16, 2021. The Scheduled Required Prepayments are $63,000 upon signing the Agreement and eight (8) monthly payments thereafter aggregating $480,000 with the remaining $607,000 outstanding under the Note due on June 16, 2021. In addition, there are mandatory prepayments in the event the Company completes a Subsequent Placement (as defined) or long-term debt (other than from the Buyer or from officers, directors and 10% or greater shareholders of the Company) or factoring and purchase order indebtedness, the Company shall effect a Company Optional Redemption amount equal to 50% of the gross proceeds (less reasonable expenses of counsel and any investment bank) together with all Scheduled Required Payments.

On June 18, 2021, the Company modified the terms of its outstanding debt by entering into a Third Forbearance Agreement (the “Third Agreement”) whereby the Company agreed to make certain payments to the creditor and the creditor will accept such payments as full discharge of the outstanding debt. The Agreement provides that the Buyer will (a) forbear (i) from taking any action with respect to the Existing Default and (ii) from issuing any demand for redemption of the Note on the basis of the Existing Default until the earlier of: (1): November 16, 2021 (or, if earlier, such date when all amounts outstanding under the Note shall be paid in full or converted into shares of Common Stock in accordance therewith) and (2) the time of any breach by the Company of the Agreement or the occurrence of an Event of Default that is not an Existing Default (the “Forbearance Expiration Date), (b) during the Forbearance Period (as defined) waive the prepayment premium to any Company Optional Redemption (which will result in the 120% redemption premium effectively replaced with 100%), and (c) during the Forbearance Period, waive the repayment in full of the Note other than the Required Payments (as defined) prior to November 16, 2021. The Scheduled Required Prepayments are $62,000 upon the first scheduled required prepayment and five (5) payments thereafter aggregating $287,000 with the remainder outstanding under the Note due on November 16, 2021. In addition, there are mandatory prepayments in the event the Company completes a Subsequent Placement (as defined) or long-term debt (other than from the Buyer or from officers, directors and 10% or greater shareholders of the Company) or factoring and purchase order indebtedness, the Company shall effect a Company Optional Redemption amount equal to 50% of the gross proceeds (less reasonable expenses of counsel and any investment bank) together with all Scheduled Required Payments. The Company performed an analysis to determine if at least a 10% difference between the present value of the new loan’s cash flows and the present value of the old loan’s remaining cash flows and determined that yes there is more than a 10% difference. The Company will experience a cash flow increase of approximately 15% due to the modification; therefore, the cash flow is considered substantially different, and the Company has applied extinguishment accounting.

The May 2019 Note is convertible at any time by the Holder into 250,000 shares of common stock, par value $0.001 per share at the rate of $6.00 per share, subject to adjustment (the “Conversion Price”). Upon an Event of Default (regardless of whether such event has been cured), the Buyer may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the then Volume-Weighted Average Price (as defined, the “VWAP”). The Company considered the need for the conversion feature to be bifurcated under ASC 815 and determined that it does not meet the requirements. Additionally, the Company determined the effective conversion rate under ASC 470-20 and determined that the instrument is out of the money and no beneficial conversion feature was recorded.

The May 2019 Note is senior in right of payment to all other existing and future indebtedness of the Company except Permitted Senior Indebtedness (as defined in the May 2019 Note), including $12 million of senior secured indebtedness of the Company and its subsidiaries under an existing senior loan agreement, plus defined amounts of purchase money indebtedness in connection with bona fide acquisitions.

The May 2019 Note includes customary Events of Default and provides that the Buyer may require the Company to redeem (regardless of whether the Event of Default has been cured) all or a portion of the Note at a redemption premium equal to the greater of: (i) the product of the redemption premium of one hundred twenty-five (125%) percent, multiplied by the conversion amount, and (ii) the product of the conversion rate ($6.00 per share) multiplied by the product of 125% multiplied by the then current market price. The Buyer may also require redemption of the May 2019 Note upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent. The Company has the right to redeem the May 2019 Note at any time, in whole or in part, in cash at a price equal to 120% of the then outstanding conversion amount.

Conversion of the May 2019 Note is subject to a blocker provision which prevents any holder from converting the May 2019 Note into shares of common stock if its beneficial ownership of the common stock would exceed 9.99% of the Company’s issued and outstanding common stock.

As of December 31, 2019, the Company had a principal balance of $907,000 on the May 2019 Note and the Company had accrued $15,420 in interest expense. During the six months ended June 30, 2021, the Company repaid $362,000 such that as of June 30, 2021, the Company had a principal balance $545,000 on the May 2019 Note and the Company had accrued $18,102 in interest expense.

Roth Capital Partners, LLC (“Roth”), as the Company’s exclusive placement agent, received a cash commission for this transaction equal to six (6%) percent of the total gross proceeds of the offering. This 6% fee or $90,000 was recorded as debt discount along with the $30,000 in legal fees associated with the May 2019 Note. These fees will be amortized over the term of the note. The Company amortized $90,491 in the year ended December 31, 2019 and the remaining $29,509 was amortized during the year ended December 31, 2020.2022.

On December 21, 2020 (the “Issue Date”), Cosmos Holdings, Inc. (“Cosmos”, the “Borrower” or the “Company”) entered into a convertible promissory note with Platinum Point Capital, LLC (the “Holder”, “Lender” or “Platinum”) pursuant to a Securities Purchase Agreement (the “SPA”).

The Company issued the $540,000 Note in exchange for $500,000 in cash and included a $40,000 Original Issue Discount (“OID”) and paid $3,000 in financing costs. The principal amount together with interest at the rate of eight percent (8.0%) per annum, compounded annually (the “Interest Rate”), will be paid to the Lenders on or before the Maturity Date (December 31, 2021 or as defined below). Accrued interest shall be calculated on the basis of a 360-day year for the actual number of days elapsed. In the event that on or before the Maturity Date, the Note either (i) ~~have~~had not been converted or have not been otherwise satisfied in full or (ii) an Event of Default (as defined in the SPA) occurs, then the applicable rate of interest on the outstanding amount of the Note since inception shall be the Interest Rate plus eighteen percent (18.0%), the Default Interest. Unless previously converted, the principal and accrued interest on the Note is due and payable in cash (USD) upon the earlier of (i) December 31, 2021, (ii) a Change of Control (as defined ~~below)~~in the SPA) or (iii), an Event of Default ~~(as defined below)~~ (collectively, the “Maturity Date”).

During the year ended December 31, 2021, the Company converted an aggregate total of $525,000 in principal and $25,144 in accrued interest and fees into 213,382 shares of the Company’s common stock at an average price per share of $2.58. Upon conversion, the 213,382 shares were issued at a fair value of $959,024 which was recorded as equity. Accordingly, upon conversion, the Company reduced its outstanding debt by $550,144, reduced its derivative liability by $284,169, and recorded a loss on extinguishment of $124,711. As of ~~June 30,~~March 31, 2022 and December 31, 2021, the Company had a principal balance of ~~$540,000~~$15,000 each period and had accrued ~~$23,400~~approximately $7,000 in interest ~~expense.~~expense each period.

The Note may be prepaid in whole or part beginning from the issue date until a date not later than 180 days thereafter, the Company shall have the right to prepay the full amount outstanding under the Note (principal and accrued interest), in full by making a payment to the Holder in an amount equal to one hundred twenty (120%) multiplied by the sum of (w) the then outstanding principal amount of this Note plus (x) accrued and unpaid interest on the unpaid principal amount of the Note plus (y) Default Interest, if any.

The Holder shall have the right at any time from the Issue Date to convert all or part of the outstanding and unpaid principal amount of the Note into Common Stock at the Conversion Price of as defined below.

The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a beneficial conversion feature and a derivative liability which is accounted for separately. The Company determined a beneficial conversion feature and derivative liability exists because The Company measured the beneficial conversion feature’s intrinsic value on December 16, 2020, and determined that the embedded derivative was valued at $456,570 which was recorded as a debt discount, and together with the original issue discount and transaction expenses of $43,000, in the aggregate of $499,570, is being amortized over the life of the loan. ~~For~~As of March 31, 2022 and December 31, 2021 and $568,826 and $494,973, respectively, of the ~~three and six months ended June 30, 2021, $71,641 and $109,865, respectively~~debt discount has been amortized. As of ~~June 30,~~March 31, 2022 and December 31, 2021, the fair value of the derivative liability was ~~$394,941~~$3,949 and ~~for~~$5,822, respectively. For the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021, the Company ~~recorded~~record a gain ~~of $21,572 and $65,787, respectively from~~on the change in fair value of the derivative ~~liability as other income in the consolidated statements~~ of ~~operations~~$1,873 and ~~comprehensive income (loss).~~$44,215, respectively.

On January 7, 2021 (the “Issue Date”), the Company entered into a subscription agreement with an unaffiliated third party, whereby the Company issued for a purchase price of $100,000 in principal amount, a convertible promissory note. The note bears an interest rate of 8% per annum and matures on the earlier of (i) consummation of the Company listing its common shares on the NEO Stock Exchange or (ii) October 31, 2021.

Upon the consummation of a NEO listing, the total principal and accrued interest outstanding on the note will convert into shares of the Company’s common stock at a 25% discount to the prices of the common shares sold in the financing to be conducted in conjunction with the NEO listing. In the event that a NEO listing is not consummated on or before October 31, 2021, the note holder will have the option, in part or in full, to have the note repaid with interest, or convert the note into Company common stock at a 25% discount to the 30-day volume-weighted average price of the Common Shares on the most senior stock exchange in North American on which the common shares are trading prior to conversion. ~~As of June 30, 2021, the Company had a principal balance of $100,000 and had accrued $3,735 in interest expense.~~

The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a beneficial conversion feature and a derivative liability which is accounted for separately. The Company measured the beneficial conversion feature’s intrinsic value on January 7, 2021, and determined that the embedded derivative was valued at $62,619 which was recorded as a debt discount and additional paid-in capital, and is being amortized over the life of the loan. ~~For~~As of March 31, 2022 and December 31, 2021, $62,619 of the ~~six months ended June 30, 2021, $29,223~~debt discount has been amortized. As of ~~June 30,~~March 31, 2022 and December 31, 2021, the fair value of the derivative liability was ~~$40,537~~$26,716 and ~~for~~$39,843, respectively. For the three ~~and six~~ months ended ~~June 30, 2021,~~March 31, 2022, the Company recorded a gain of ~~$4,924 and $22,082, respectively~~$13,127 from the change in fair value of derivative liability as other income in the consolidated statements of operations and comprehensive income (loss).

On September 17, 2021 (the “Issue Date”), the Company entered into a convertible promissory note and securities purchase agreement with an unaffiliated third party.

The Company issued the convertible promissory note for a purchase price of $525,000 in principal amount for cash proceeds of $500,000. The note was issued with an original issue discount (“OID”) of $25,000, bears an interest rate of 10% per annum and matures on the earlier of (i) the consummation of the Company listing its common shares on the Nasdaq Stock Market or (ii) September 17, 2022.

Upon the consummation of a Nasdaq listing, the total principal and accrued interest outstanding on the note will convert into shares of the Company’s common stock at a 30% discount to the prices of the common shares sold in the financing to be conducted in conjunction with the Nasdaq listing, subject to a conversion floor of $3.00. The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a beneficial conversion feature which is accounted for separately. The Company measured the beneficial conversion feature’s intrinsic value on September 17, 2021, at $294,000 which, together with the OID of $25,000 was recorded as a debt discount and is being amortized over the life of the loan. For the year ended December 31, 2021, $60,063 of the debt discount has been amortized. As of December 31, 2021, the Company had accrued a principal balance of $525,000, had accrued $15,166 in interest expense, and had remaining debt discount of $258,937 which resulted in a net convertible note payable of $266,063.

For the three months ended March 31, 2022, $127,916 of the debt discount has been amortized. As of March 31, 2022, the Company had accrued a principal balance of $525,000, had accrued $28,291 in interest expense, and had remaining debt discount of $191,084 which resulted in a net convertible note payable of $333,916.

The table below provides a summary of the changes in fair value, including net transfers in and/or out of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three ~~and six~~ months ended ~~June 30, 2021:~~March 31, 2022:

	Amount			Amount
Balance on December 31, 2020	$	460,728
Balance on January 1, 2022				$	45,665
Issuances to debt discount		62,619			0
Reduction of derivative related to conversions					0
Change in fair value of derivative liabilities		(85,869	)		(15,001	)
Balance on June 30, 2021	$	437,478
Balance on March 31, 2022				$	30,664

The fair value of the derivative conversion features and warrant liabilities as of ~~June 30,~~March 31, 2022 and December 31, 2021 were calculated using a Monte-Carlo option model valued with the following assumptions:

A summary of the Company’s third-party debt ~~during the six months ended June 30, 2021~~as of March 31, 2022 and ~~the year ended~~ December 31, ~~2020 is~~2021 presented below:

June 30, 2021	Loan Facility			Trade Facility			Third Party			COVID Loans			Total
March 31, 2022																Loan Facility			Trade Facility			Third Party			COVID Loans			Total
Beginning balance		3,302,100			6,446,000			12,631,284			435,510			22,814,594		$	1,299,784		$	6,207,010		$	10,077,977		$	234,117		$	17,818,888
Proceeds		0			0			0			0			0			0			-			-			-			-
Payments		(20,000	)		0			0			0			(20,000	)		(124,242	)		(107,894	)		(2,030,814	)					(2,262,950	)
Conversion of debt		0			0			(3,010,000	)		0			(3,010,000	)		(1,190,000	)		-						-			(1,190,000	)
Recapitalized upon debt modification																	-			(198,040	)		(1,204,356	)		-			(1,402,396	)
Accretion of debt																	78,445			-						-			78,445
Foreign currency translation		(106,836	)		(76,400	)		(19,460	)		(10,740	)		(213,382	)		54,861			(41,505	)		(21,433	)		(5,029	)		(13,106	)
Subtotal		3,175,264			6,369,600			9,601,878			424,470			19,571,212			118,848			5,859,571			6,821,374			229,088			13,028,881
Reclass of long-term portion of debt		(2,582,864	)		(2,191,880	)		(5,460,759	)		0			(10,235,503	)
Ending Balance		592,400			4,177,720			4,141,119			424,470			9,335,709
Notes payable - long-term																	-			-			(6,664,025	)		(221,781	)		(6,885,806	)
Notes payable - short-term																$	118,848		$	5,859,571		$	157,349		$	7,307		$	6,143,075

December 31, 2020	Loan Facility			Bridge Loans			Trade Facility			Third Party			COVID Loans		Total
December 31, 2021																		Loan Facility			Trade Facility			Third Party			COVID Loans			Total
Beginning balance		3,078,442			191,287			6,245,400			2,514,595			0		12,029,724		$	3,302,100		$	6,446,000		$	12,631,284		$	435,210		$	22,814,594
Proceeds		0			0			0			16,121,500			435,210		16,556,710			-			-			565,900			-			565,900
Payments		0			(191,287	)		0			(5,006,115	)		0		(5,230,725	)		(141,475	)		(57,835	)		(62,878	)		(3,233	)		(265,421	)
Conversion of debt											(807,795	)				(807,795	)		(1,606,500	)		-			(3,010,000	)		-			(4,616,500	)
Debt extinguishment		(12,066	)		0			0			(192,205	)		0		(204,271	)
Recapitalized upon debt modification																			(86,670	)		-			-			-			(86,670	)
Debt forgiveness																			-			-			-			(169,770	)		(169,770	)
Foreign currency translation		269,047			0			200,600			1,304			0		470,951			(167,671	)		(181,155	)		(46,329	)		(28,090	)		(423,245	)
Subtotal		3,302,100			0			6,446,000			12,631,284			435,210		22,814,594			1,299,784			6,207,010			10,077,977			234,117			17,818,888
Reclass of long-term portion of debt		(2,843,475	)		0			(2,384,850	)		(5,543,557	)		0		(10,771,882	)
Ending Balance		458,625			0			4,061,150			7,087,727			435,210		12,042,712
Notes payable - long-term																			-			(2,450,000	)		(9,854,906	)		(51,478	)		(12,356,384	)
Notes payable - short-term																		$	1,299,784		$	3,757,010		$	223,071		$	182,639		$	5,462,504

On ~~June 30, 2020, SkyPharm~~August 4, 2021, the Company entered into ~~a settlement~~an exchange agreement ~~on an~~for the existing loan facility agreement with Synthesis Peer-to-Peer Income Fund, whereby the Company agreed to ~~make certain payments to~~ the creditor and the creditor will accept such payments as full discharge of outstanding debt. In accordance with the settlement agreement, interest will accrue from June 30, 2020 until repayment in full at a rate of 6% per annum for the first year and 5.25% per annum for the second year calculated on the balance outstanding from day to day during such period. Interest is due on the 10^th day of each calendar month. If any amount of principal or interest is unpaid on its due date interest shall accrue from the due date until the date of its payment until the date of its payment in full at the rate of 7.25% per annum. The Company will make quarterly payments of €125,000 beginning May 6, 2021 with a final payment of €2,200,000 on May 6,following:

The Company evaluated the ~~settlement~~August 4, 2021, exchange agreement for debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment asbecause a substantial conversion feature was added to the ~~10% cash flow test was met. As~~debt terms. Upon extinguishment, the Company recorded a ~~result, the $3,828,630 of principal and accrued interest of $168,732, or an aggregate of $3,997,362 was written off and the new debt was recorded at fair value as of June 30, 2020~~loss upon extinguishment in the amount of ~~$3,033,990.~~$6,642 and recorded the new debt at fair value based on the present value of future cash flows using a discount rate of 11.66%. As of March 31, 2022 and December 31, ~~2020,~~2021, the Company has accrued interest expense of ~~$33,021~~$16,849 and $4,414, respectively, and the principal balance of the debt is ~~$3,302,100, of~~$118,848 and $1,299,784, respectively, which ~~$2,843,475~~ is classified as Notes payable ~~– long term portion~~ on the consolidated balance sheet. As of June 30, 2021, the Company repaid $23,696 and the principal balance of the debt is $3,175,264, of which $2,582,864 is classified as Notes payable – long term portion on theunaudited condensed consolidated balance sheet.

The debt is subject to acceleration in an Event of Default (as defined in the Notes). This agreement is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas.

On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “SkyPharm Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”)~~. The SkyPharm Facility provides the following material terms:~~

~~The Company obtained consents from Synthesis Peer-to-Peer Income Fund in connection with obtaining the Lender.~~

On as amended on November 16, 2017, SkyPharm signed an amended agreement with Synthesis Structured Commodity Trade Finance Limited that increased the maximum aggregate facility limit from €2,000,000 ($2,291,200) to €6,000,000 ($6,736,200). All other terms of the original agreement remain the same. The Company also obtained consents from Synthesis Peer-to-Peer Income Fund in connection with obtaining the November 2017 convertible debt financing.

~~On May 12, 2018, the Company borrowed an additional €270,000 ($247,117) in funds.~~

Onand May 16, 2018, SkyPharm S.A., as Commodity Buyer, entered into a Supplemental Deed of Amendment (the “Deed”) relating to a Trade Finance Facility dated May 12, 2017, as amended, with Synthesis Structured Commodity Trade Finance Limited (“Synthesis”), as Loan Receivables Originator. Under the Trade Finance Facility (the “TFF”) first entered into on May 12, 2017, as amended, there was a principal balance of €5,866,910 ($5,369,678) outstanding as of June 30, 2018. SkyPharm made a payment of €1,000,000 ($1,123,600) of interest and principal on May 31, 2018 under the terms and conditions of the Deed. Additionally, the maturity date for the facility has been amended such that, the full principal amount is to be repaid no later than May 31, 2021, subject to a repayment schedule to be agreed upon by SkyPharm and Synthesis Structure Commodity Trade Finance Limited. Synthesis Structure Commodity Trade Finance Limited may extend this final repayment date at its sole discretion.

The Deed is conditioned upon, among other things, execution and perfection of a Bulgarian Amended Pledge (“BAP”) having priority over the Bulgarian Pledge Accounts with Unicredit Bulbank AD; and the Approved Purchasers are to make all payments to SkyPharm directly to the BAP.

On May 16, 2018, SkyPharm and Synthesis also entered into an Account Merge Agreement (the “Pledge”) as a requirement under the above-described Deed. Under the Pledge, Synthesis is to receive a first ranking securities interest in SkyPharm’s outstanding receivables under the Bulgarian bank account.

On October 17, 2018, the Company entered into a further amended agreement with Synthesis whereby the current balance on the TFF as of October 1, 2018, which was €4,866,910 ($5,629,555) and related accrued interest of €453,094 ($524,094) would be split into two principal balances of Euro €2,000,000 and USD $4,000,000. Interest on the new balances commenced on October 1, 2018, at 6% per annum plus one-month Euribor, when it is positive, on the Euro balance and 6% per annum plus one-month Libor on the USD balance.

The ~~Company will repay the principal amounts of each balance beginning no later than August 31, 2018 in quarterly installments of €125,000 and US $150,000. The~~USD $4,000,000 loan ~~matures~~matured on August 31, 2021. ~~The~~On March 3^rd 2022, the Company ~~evaluated~~entered into an extension to the ~~amended agreement under ASC 470-50 and concluded that it did not meet~~facility agreement. Based on the ~~10% cash flow test and recorded debt modification expense of $138,110.~~updated repayment terms, the facility’s final repayment date was extended to January 2023.

AsOn December 30, 2020, the Company transferred the Euro €2,000,000 loan to a new third-party lender. The terms remained the same except interest will now accrue at 5.5% per annum plus Euribor. The principal is to be repaid in a total of five quarterly installments beginning October 31, 2021 of 50,000 Euro each with a final repayment of 1,800,000 Euro payable on the earlier of 24 months after December 30, 2020 or October 31, 2022.

During the year ended December 31, 2021, the Company repaid $56,508 of the €2,000,000 balance such that as of December 31, ~~2020,~~2021, the Company had principal balances of ~~€2,000,000~~€1,950,000 ($~~2,446,000),~~2,207,010) and $4,000,000 under the agreements, of which ~~$2,384,850~~$2,450,000 is classified as ~~Notes payable – long~~notes payable-long term ~~portion~~ on the consolidated balance sheet and ~~$4,000,000 under the agreements and~~ the Company had accrued ~~$402 and $16,185 respectively,~~$10,466 in interest expense related to these agreements. As

On March 3, 2022, the Company entered into a modification agreement to extend the maturity date to January 10, 2023 and payments under the $4,000,000 loan. The loan was considered a modification under ASC 470-50 because the change in the present value of ~~June 30, 2021,~~cash flows is less than 10%. The Company capitalized fees paid upon modification of $200,000 that are being amortized over the life of the loan. During the three months ended March 31, 2022, the Company repaid $55,465 of the €1,950,000 balance and $50,059 of the $4,000,000 balance such that as of March 31, 2022, the Company had principal balances of ~~€2,000,000~~€1,900,000 ($~~2,369,600), of which $2,191,880 is classified as Notes payable – long term portion on the consolidated balance sheet,~~2,107,670) and ~~$4,000,000~~$3,751,901 under the agreements ~~and~~which are recorded as short term. As of March 31, 2022, the Company had accrued ~~$11,250 and $26,231 respectively,~~$81,813 in interest expense related to these agreements.

On November 16, 2015, the Company entered into a Loan Agreement with Panagiotis Drakopoulos, former Director and former Chief Executive Officer, pursuant to which the Company borrowed €40,000 ($42,832) as a note payable from Mr. Drakopoulos. The note bears an interest rate of 6% per annum and was due and payable in full on November 15, 2016. As of December 31, ~~2020, the Company had an outstanding principal balance of €8,000 ($9,784) and accrued interest of €4,785 ($5,852). As of June 30,~~ 2021, the Company had an outstanding principal balance of €8,000 ($~~9,478)~~9,054) and accrued interest of ~~€6,066~~€6,318 ($~~7,187)~~7,151). As of March 31,2022, the Company had an outstanding principal balance of €8,000 ($8,874) and accrued interest of €6,439 ($7,143).

In the years ending December 31, 2019 and 2020, the Company executed Senior Promissory Notes (the “Debt”) in an aggregate total of $3,010,000 to an unaffiliated third-party lender (the “Lender”). As of December 31, 2020, the Company had a principal balance of $3,010.00 on this Debt and the Company had accrued $527,604 in interest expense. As of February 5, 2021, The Company entered into an Amended and Restated Debt Exchange Agreement (the “Agreement”) with the “Lender that provided for the issuance by the Company of 781,819 shares of common stock (the “Exchange Shares”), at the rate of $3.85 per share, in exchange for an aggregate of $3,010,000 principal amount of existing loans made by the Lender to the Company. The market price at the time this Agreement was negotiated was $3.28 per share and the Company recorded a gain on debt extinguishment of $445,636.

All accrued and unpaid interest, $563,613 as of June 30, 2021, as well as any unpaid fees, shall be paid in three (3) equal monthly installments following the closing of a planned Canadian public offering. Pursuant to this Agreement, Grigorios Siokas, the Company’s Chief Executive Officer and principal shareholder, will be released from all personal guarantees on the Debt.

May 18, 2020, ~~and~~ July 3, 2020, and August 4, 2020 Senior Promissory Notes

On May 18, 2020, the Company executed a Senior Promissory Note (the “May 18 Note”) in the principal amount of $2,000,000 payable to an unaffiliated third-party lender. The May 18 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 18 Note matured on December 31, 2020. ~~The note is not in default and the Company is currently in negotiations with the lender~~

Notes to ~~extend the maturity date.~~Unaudited Condensed Consolidated Financial Statements

The May 18 Note is subject to acceleration in an Event of Default. Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the May 18 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of ~~June 30, 2021 and~~ December 31, ~~2020,~~2021 the Company had a principal balance of $2,000,000 on this ~~note.~~note, which is classified as Notes payable – long term portion on the consolidated balance sheet.

On July 3, 2020, the Company executed a Senior Promissory Note (the “July 3 Note”) in the principal amount of $5,000,000 payable to an unaffiliated third-party lender. The July 3 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The July 3 Note matures on June 30, 2022 unless in default.

The July 3 Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the July 3 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection.

The Company used the proceeds from the July 3 Note to repay the principal outstanding on the May 5 Note ($2,000,000), the May 8 Note ($2,000,000), and the February Note ($1,000,000). As of ~~June 30, 2021 and~~ December 31, ~~2020,~~2021, the Company had a principal balance of $5,000,000 on this note, which is classified as ~~long-term~~Notes payable – long term portion on the consolidated balance sheet.

As of ~~June 30, 2021 and~~ December 31, ~~2020,~~2021, the Company ~~has~~had accrued an aggregate total of ~~$259,149 and $146,685~~$210,574 in ~~accrued~~ interest expense related to these loans.

On August 4, 2020, the Company executed a Senior Promissory Note (the “August 4 Note”) in the principal amount of $3,000,000 payable to an unaffiliated third-party lender. The August 4 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The August 4 Note matured on December 31, ~~2020 unless in default. The note is not in default and the Company is in negotiations with the lender to extend the maturity date.~~2020.

The August 4 Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the August 4 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection.

On October 29, 2020, the Company entered into a debt exchange agreement with the lender whereby the Company issued 259,741 shares of common stock at the rate of $3.85 per share in exchange for an aggregate of $1,000,000 principal amount of the existing loan. The fair market value of the Company’s common stock on the date of exchange was $3.11 per share and as such, the Company recorded a gain of $192,205. Interest ~~will continue~~continued to accrue on the remaining debt and the converted amount until December 31, 2020. As of December 31, 2020, the Company had a principal balance of $2,000,000 on this note and prepaid interest of $8,514. As of ~~June 30,~~December 31, 2021, the Company had a principal balance of $2,000,000 on this note, which is classified as Notes payable – long term portion on the consolidated balance sheet, and $0$60,166 in accrued interest expense. ~~The note is not in default~~

Modification of May 18, 2020, July 3, 2020, and August 4, 2020 Senior Promissory Notes

On February 23, 2022, the Company ~~is in negotiations with the lender~~entered into modification agreements to extend the ~~maturity date.~~due dates of the May 18 Note, July 3 Note, and August 4 Note to June 30, 2023 of $9,000,000, in the aggregate. The Company paid restructuring fees totaling $506,087 upon modification. The Company determined the modification should be recorded as debt extinguishment in accordance with ASC 470 because the present value of the remaining cash flows under the terms of the new debt instrument is at least 10% different from the present value of the remaining cash flows under the terms of the original instrument. The Company recorded the new debt at fair value in the amount of $7,706,369 and a gain upon extinguishment in the amount of $787,544. During the three months ended March 31, 2022, the Company made principal payments in the amount of $2,000,000 and recorded non-cash interest expense in the amount of $89,275 for the accretion of debt. As of March 31, 2022, the Company had a principal balance of $5,795,644 in relation to the May 18 Note, July 3 Note, and August 4 Note, in the aggregate. As of March 31, 2022, the Company has accrued an aggregate total of $443,341 of accrued interest on these notes, in the aggregate.

On November 19, 2020, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($611,500). The note matures on November 18, 2025 and bears an annual interest rate, based on a 360-day year, of 3.3% plus .6% plus 6-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a six-month grievance from the first deposit date, which was November 19, 2020, for principal repayment. The principal is to be repaid in 18 quarterly installments of €27,000 with the first payment due 9 months from the first deposit. During the year ended December 31, 2021, the Company repaid €55,556 ($62,878) of the principal and as of December 31, 2021, the Company has accrued interest of $5,642 related to this note and a principal balance of €444,444 ($503,022), of which $377,270 is classified as Notes payable – long term portion on the consolidated balance sheet. During the three months ended March 31, 2022, the Company repaid €27,778 ($30,814) of the principal and as of March 31, 2022, the Company has accrued interest of $4,815 related to this note and a principal balance of €416,667 ($462,208), of which $429,582 is classified as Notes payable – long term portion on the consolidated balance sheet

On July 30, 2021, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($578,850). The note matures on August 5, 2026 and bears an annual interest rate that applies to 60% of the principal of the note that is based on a 365-day year, of 5.84% plus 3-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a six-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 18 quarterly installments of €27,000 commencing three months from the end of the grace period. As of December 31, ~~2020,~~2021, the Company ~~had no~~has accrued interest of $3,100 and a principal balance of €500,000 ($~~611,500)~~565,900), of which ~~$543,557~~$477,637 is classified as Notes payable – long term portion on the consolidated balance sheet. As of ~~June 30, 2021,~~March 31, 2022, the Company ~~had no~~has accrued interest of $3,042 and a principal balance of €500,000 ($~~592,400)~~554,650), of which ~~$460,759~~$438,799 is classified as Notes payable – long term portion on the accompanying condensed consolidated balance sheet. ~~As of June 30, 2021 the Company has $8,856 in accrued interest expenses related to this note.~~

On May 12, 2020, the ~~Company~~Company’s subsidiary, SkyPharm, was granted and on May 22, 2020 the Company received a €300,000 ($~~337,110)~~366,900) loan from the Greek government. The loan will be repaid in 40 equal monthly ~~instalments~~installments beginning on January 1, 2022 and bears an interest rate of 0.94% per annum. As a condition to the loan, the ~~company is~~Company was required to retain the same number of employees until October 31, 2020. ~~The~~During the year ended December 31, 2021, the Company received a waiver of 50% forgiveness of the loan and recorded $177,450 as other income. As of December 31, 2021 the principal balance aswas $169,770. As of ~~June 30, 2021~~March 31, 2022, the principal balance was ~~$355,440.~~$166,395.

On June 24, 2020, the Company received a loan £50,000 ($~~61,845)~~68,310) from the United Kingdom government. The loan has a six-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement. The Company may prepay this loan without penalty at any time. The Company repaid £2,335 ($3,233) of principal during the year ended December 31, 2021, and the balance as of ~~June 30,~~December 31, 2021 was ~~$69,030.~~£47,665 ($64,347). As of March 31, 2022, the principal balance was £47,665 ($62,693).

As discussed in Note 3 above, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon. The Company was appointed the exclusive distributor of the Products (as defined) initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. As consideration for its services, Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in Common Shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000.

As discussed in Note 3, the Company attributed no value to the shares received in Marathon pursuant to (a) above. In relation to the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). If settlement were to occur on December 31, 2019, the Company would be required to issue ~~261,891~~635,829 common shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. If such events were to occur, the Company would be required to increase its authorized share capital and since increasing the authorized share capital is within the control of the Company, as our CEO controls greater than 50% of the outstanding common stock of the Company, the original classification of equity-classified financial

The Company has various lease agreements with terms up to 10 years, comprising leases of office ~~space.~~space, cars leases for the distribution of pharmaceutical products, equipment hires, etc. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised.

The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet.

The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the interest rate of our long-term debt on the date of inception.

The Company’s weighted-average remaining lease term relating to its operating leases is ~~6.71~~6.47 years, with a weighted-average discount rate of 6.74%.

The Company incurred lease expense for its operating leases of ~~$99,610~~$54,124 and ~~$104,588~~$65,577 which was included in “General and administrative expenses,” for the ~~six~~three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively.

The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of ~~June 30, 2021.~~March 31, 2022.

Maturity of Lease Liability
Remainder of 2021	$	115,368
2022		228,112
Remainder of 2022				$	154,095
2023		203,409			177,914
2024		118,978			108,485
2025		114,856			108,485
Thereafter		431,790			408,810
Total undiscounted operating lease payments	$	1,212,513		$	957,789
Less: Imputed interest		(243,054	)		(182,247	)
Present value of operating lease liabilities	$	969,459			775,542

The Company’s weighted-average remaining lease term relating to its finance leases is ~~2.7~~2.93 years, with a weighted-average discount rate of 6.74%.

The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s finance leases as of ~~June 30, 2021.~~March 31, 2022.

~~The Company had operating cash flows used in finances leases of $4,453 and $2,301 for the six months ended June 30, 2021 and 2020, respectively.~~

The Company incurred interest expense on its finance leases of ~~$5,250~~$3,507 which was included in “Interest expense,” for the ~~six~~three months ended ~~June 30, 2021.~~March 31, 2022. The Company incurred amortization expense on its finance leases of ~~$49,267~~$19,580 which was included in “Depreciation and amortization expense,” for the ~~six~~three months ended ~~June 30, 2021.~~March 31, 2022. The total cash used for the Company’s finance leases for the three months ended March 31, 2022 amounted to $22,358.

From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of ~~June 30, 2021, there~~March 31, 2022, the following litigations were ~~no pending or threatened lawsuits that could reasonably be~~pending. None of the below is expected to have a material ~~effect on~~financial or operational impact.

Solgar Inc. is suing SkyPharm SA for product homogeneity regarding the ~~results~~nutraceutical line "Sky Premium Life". As a result, Solgar requested the prohibition for SkyPharm to manufacture, import and sell, market or in any way possess and distribute, including Internet sales and advertise in any way in the Greek market of "Sky Premium Life" due to homogeneity with Solgar's products. Lawsuit with data no 4545/2021 of the ~~Company’s operations.~~

~~On April 18, 2018,~~company "Solgar Inc." against SkyPharm ~~S.A. entered into a ten-year Advisory Agreement with Synthesis Management Limited (the “Advisor”)~~before the Court of First Instance of Thessaloniki, according to which Solgar Inc. requests to prohibit SkyPharm SA's use of the nutraceutical line "Sky Premium Life" packages as its characteristics are similar to Solgar Inc.’s and is also seeking the withdrawal of existing ones from the market. Solgar Inc. has further requested to be awarded compensation for non-pecuniary damage amounting to 20,000€ (financial obligation). The ~~Advisor~~case was ~~retained to assist SkyPharm to secure corporate finance capital. The Advisor shall be paid €104,000 per year during the ten-year term.~~

~~On May 17, 2021, Doc Pharma~~heard on January 28, 2022 and the Company ~~entered into~~is awaiting a ~~Research and Development agreement whereby DOC Pharma~~decision. The lawyer assesses that the outcome of the trial's decision will be ~~responsible~~positive for SkyPharm SA.

Compilation and submission of a memorandum against the National Medicines Agency with no. 127351/16.12.2021 document. On July 22, 2015, the National Medicines Agency approved the license of wholesale sale of pharmaceutical products of the pharmaceutical company under the name SkyPharm SA with set validity at five years and an expiration date of July 22, 2022. Subsequently, SkyPharm SA on June 15, 2020, legally and timely submitted the application for renewal of the wholesale license of pharmaceutical products to the National Medicines Agency even though the period under review is characterized by the Covid - 19 pandemic The National Medicines Agency did not respond, therefore the Company asked from the lawyer to immediately ask for the ~~research, development~~decision of the renewal. Two months after the filing of no. 3459 / 15.01.2021 letter of the attorney and ~~design of 250 nutritional supplements~~almost nine months after the no. 627615.06.2020 company application for the ~~final products called “Sky Premium Life”~~renewal and the National Medicines Agency replied by rejecting the renewal request on March 9, 2021 (ref. 62769 / 20-25.02.2021). ~~These products will be sold in Greece and abroad. The total cost~~In addition, document No. 127351-16.12.2021 of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000) The agreement terminates on December 31, 2025.

AsEOF to SkyPharm states that after an inspection of ~~June 30, 2021, there were 37,000 options outstanding and 37,000 options exercisable with expiration dates of January 2022.~~

~~A summary~~EOF at the premises of the ~~Company’s option activity during~~company "Doc Pharma", SkyPharm did not have a wholesale license in force in violation of article 106 par. 1b and par. 1c of the ~~six months ended June 30,~~ministerial decision D.YG3a / GP.32221 / 29-4-2019 and issued invoices dated February 26, 2021 ~~is presented below:~~

~~As of June 30, 2021, there were 1,164,673 warrants outstanding~~ and ~~1,164,673 warrants exercisable with expiration dates from May 2023 through~~ March ~~2024.~~8, 2021). The National Medicines Agency has not yet replied to the renewal request.

~~A summary~~Order for payment by the court which derived from a fine related to tax audit that concerns financial year 2014. The ruling with no. 483/16.12.2020 was against Cosmofarm SA. The defendant appealed against the decision by the ruling with no.11541/09.03.2021.This appeal was dismissed due to inactive passage of 120 days. Because of this inactive passage, Cosmofarm appealed against Greek tax authorities, no.6704/29.11.2021. There was an obligation of additional tax and fines imposition of 91,652.27€ that Cosmfarm has already paid and claim back through the ~~Company’s warrant activity during~~appeal (financial claim). The trial is pending. The lawyer assesses that they cannot assume the ~~six months ended June 30, 2021 is presented below:~~final outcome of this case.

ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc.). ASC 606-10-55-89 explains that the extent to which an entity’s revenue is disaggregated depends on the facts and circumstances that pertain to the entity’s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue.

~~The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue.~~

~~The following table presents our revenue disaggregated by country for the three months ended:~~

~~The following table presents our revenue disaggregated by country for the six months ended:~~

On July 1, 2021, the Company entered into a two-year advisory agreement with a third party (the “Consultant”) for advisory and consulting services related to the Company’s intention to become listed on NASDAQ. Peter Goldstein, a then director of the Company is a principal of the Consultant. As consideration for services rendered, the Company will pay the consultant $4,000 a month until the Company commences trading on NASDAQ. Upon NASDAQ listing, the Company shall pay $10,000 per month, with $4,000 per month paid on a monthly basis and $6,000 per month accrued until such time as the Company raises an aggregate of $10,000,000. In addition, the consultant will receive a $100,000 bonus upon NASDAQ listing and when the Company has raised an aggregate of $10,000,000. Finally, the Company has agreed that the Consultant shall receive a total of 250,000 shares of the Company’s common stock, 50,000 of such shares that have been previously issued pursuant to previous agreements and 200,000 shares to be issued when the Company commences trading on NASDAQ.

On July 7, 2021, the Company entered into an agreement with a non-exclusive financial advisor and placement agent. The term of the agreement is a minimum of 45 days and will continue until 5 business days following the date in which a party receives written notice from the other party of termination. As consideration for services rendered, the Company shall pay: a) a cash fee equal to 10% of the gross proceeds of any securities sold in the offering payable at closing of the offering from the gross proceeds of the offering; b) 1% of the gross proceeds of any securities sold in the offering payable at closing of the offering from the gross proceeds of the offering for unaccountable expenses; c) warrants to purchase shares of the Company’s common stock equal to 10% of the number of shares issued in the offering or to be issued thereafter upon conversion of any convertible securities issued in the offering. These warrants will have a 5-year term and an exercise price equal to the price per share of common stock sold in the offering or conversion or exercise price into common stock of any convertible security sold and will have the same provisions, terms, conditions, rights and preferences as the securities sold in the offering; d) a cash fee equal to 10% of the exercise price of all securities constituting warrants, options or other rights to purchase securities sold in the offering payable only upon exercise.

On July 7, 2021, the Company entered into a 6-month agreement with a non-exclusive agent, advisor or underwriter in any offering of securities of the Company. At the closing of any offering the ~~company~~Company will compensate the agent: a) a cash fee or as an underwritten offering an underwriter discount equal to 7% of the aggregate gross proceeds raised in each offering. For all investors referred directly to the Company by the agent, a cash fee or as an underwritten offering an underwriter discount equal to 5% of the aggregate gross proceeds invested by such investors. b) ~~The~~the Company shall issue to ~~Spartan~~the agent or its designees at each closing, warrants to purchase shares of the Company’s common stock equal to 5% of the aggregate number of shares of common stock placed in each offering. c) ~~Out~~out of the proceeds of each closing, the Company also agreed to pay the agent up to $35,000 for non-accountable expenses (up to $50,000 for a public offering) along with up to $50,000 for fees and expenses of legal counsel and other out-of-pocket expenses (increase to up to $100,000 for public offerings) plus additional miscellaneous costs. The agent would also have the right of first refusal from the date of the agreement until the 12-month anniversary following consummation of any offerings for total proceeds of at least $3 million raised by investors introduced by the agent.

On July 13, 2021, the Company entered into a Debt Exchange Agreement (the “Agreement”) with Grigorios Siokas, the Company’s Chief Executive Officer. The Agreement provided for the issuance by the Company of 166,667 shares of common stock, at the rate of $6.00 per share, or an aggregate of $1,000,000, in exchange for $1,000,000 of existing loans by Mr. Siokas to the Company.

On July 19, 2021, the Company entered into a Debt Exchange Agreement (the “July 19 Agreement”) with Grigorios Siokas, the Company’s Chief Executive Officer. The July 19 Agreement provided for the issuance by the Company of 208,333 shares of common stock, at the rate of $6.00 per share, or an aggregate of $1,250,000, in exchange for $1,250,000 of existing loans by Mr. Siokas to the Company.

~~On July 14, 2021, pursuant to a conversion notice, $150,000 in principal and $24,144 in interest were converted at $3.165 into 55,021 shares of common stock.~~

On July 20, 2021, the Company entered into a Convertible Promissory Note with Greg Siokas, CEO, in the principal amount of $2,000,000 memorializing outstanding loans to the Company. The note is due on demand and will not bear interest if it is paid before the maturity date. The note may be prepaid without penalty at any time and is convertible at the option of the holder at any time at any time at above the then current market price. Pursuant to the July 20, 2021 Agreement, an aggregate of $1,250,000 of indebtedness was converted into equity.

On August 4, 2021, the Company entered into a debt exchange agreement (the “Agreement”) with a senior institutional lender and Grigorios Siokas, CEO, as guarantor. The parties to the Agreement had entered into a senior loan, as amended, as of June 30, 2020 (the "Loan") pursuant to which the Loan had been reduced to €2,700,000 (See note 11). The Agreement provides for the issuance by the Company of 321,500 shares of common stock (the "Exchange Shares"), at the rate of $5.00 per share, in exchange for the repayment of €1,350,000 ($1,599,480) principal amount effective upon the closing of the Agreement and 238,000 shares at an exchange rate of $5.00 per share, or at market value if the price is above $5.00 per share effective upon approval of listing of the Company’s common stock on NASDAQ in exchange for €1,000,000 ($1,184,800) of the debt.

A summary of the Company’s option activity during the three months ended March 31, 2022 is presented below:

As of March 31, 2022, there were 2,949,411 warrants outstanding and 2,949,411 warrants exercisable with expiration dates from May 2023 through August 2027.

A summary of the Company’s warrant activity during the three months ended March 31, 2022 is presented below:

The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue.

The following table presents our revenue disaggregated by country for the three months ended:

On May 1, 2022 the Company issued 39,339 shares of common stock to convert $26,515 principal and accrued interest in accordance with a convertible promissory note issued to Platinum Point Capital LLC. Following the conversion, the outstanding balance of the above Note is $0.

Effective April 28, 2022, Peter Goldstein resigned from the Board of Directors (the “Board”) the Company and from the Board’s audit committee. Mr. Goldstein’s resignation did not result from any disagreement concerning any matter relating to the Company’s operations, policies or practices.

On April 28, 2022, the Board appointed Dr. Anastasios Aslidis to the Board of Directors and as a member of the Board’s audit committee.

On April 27, 2022, the Company issued 455,316 shares of common stock upon the cashless exercise of 739,374 warrant shares.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion should be read in conjunction with our interim Condensed Consolidated Financial Statements and the related notes and other financial information appearing elsewhere in this report as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Form 10-K for the year ended December 31, ~~2020~~2021 (“Form 10-K”) and this Quarterly Report on Form 10-Q for the quarter ended ~~June 30, 2021.~~March 31, 2022.

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.

We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.

Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Cosmos Holdings, Inc. was formed as a Nevada incorporation on July 07, 2009, under the name of Prime Estates & Developments Inc. Effective September 27, 2013, we acquired 100% ownership of Amplerissimo Ltd., a private company whose principal activities included providing consulting services to various industries. On November 14, 2013, we changed our name to Cosmos Holdings, Inc. and changed our focus and business strategy to the healthcare and pharmaceutical industry. The Company, through Amplerissimo Ltd, formed SkyPharm S.A. on August ~~01,~~1, 2014, a Greek ~~Corporation~~corporation which focuses on ~~pharmaceutical products and is engaged in~~ the trading of ~~branded and generic pharmaceutical products and medicines across the European Union member states.~~nutraceutical products. On February 10, 2017, we acquired 100% ownership of Decahedron Ltd., a United Kingdom company, ~~whose principal~~which is a fully licensed wholesaler of pharmaceutical products, and its primary activity is the ~~same as the business~~trading, distribution, import and export of ~~SkyPharm S.A.~~pharmaceuticals and nutraceuticals. In addition, on December 19, 2018, the Company acquired 100% ownership of Cosmofarm Ltd, a Greek company which is a pharmaceutical wholesaler and networks with over 1,500 pharmacies.

Cosmos Holdings Inc is an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices. The Company ~~operates~~uses a differentiated operating model based on a lean, nimble and decentralized structure, with an emphasis on acquisitions of established companies and our ability to maintain better pharmaceutical assets than others. This operating model and the execution of its corporate strategy are designed to enable the Company to achieve sustainable growth and create added value for our shareholders. In particular, the Company aims to enhance its pharmaceutical and over-the-counter product lines by acquiring or licensing rights to additional products and regularly evaluate selective company acquisition opportunities. The Company, through its subsidiaries, is operating within the pharmaceutical industry and in order to compete successfully in the ~~import/export~~healthcare industry, must demonstrate that its products offer medical benefits as well as cost advantages. Currently, most of the products that the Company is trading, compete with other products already on the market in the same therapeutic category, and ~~wholesale distribution of branded pharmaceutical~~are subject to potential competition from new products ~~generic pharmaceuticals, over~~that competitors may introduce in the ~~counter (OTC) products and a variety of nutraceuticals, including its own branded label.~~future.

The Company continues to rapidly expand its distribution network worldwide and open new markets for its proprietary line of branded pharmaceuticals, nutraceuticals, and nutraceuticals through its distribution channels and ecommerce marketplace. The Company uses its extensive network with direct access to Europe’s primary sales channels for pharmaceuticals and nutraceuticals, which includes over 160 pharmaceutical wholesale distributors in Europe’s largest markets, over 40,000 pharmacies in Europe and 1,500 pharmacies in Greece. The Company achieves stable supply of pharmaceuticals from Doc Pharma which enhances its ability to scale its expansion. It receives full priority in the production of nutraceuticals and volumes. Its full production in Greece ensures a decisive production cost advantage whilst it secures additional discounts by leveraging its purchasing scale.

The Company operates in the wholesale distribution of branded pharmaceutical products, over the counter (“OTC”) products, medical devices, vitamins and a variety of nutraceuticals, including its proprietary label.

We conduct wholesale import and export of branded pharmaceutical products throughout Europe by our ~~subsidiaries, SkyPharm S.A. and Decahedron Ltd.~~subsidiaries. We source licensed pharmaceuticals from wholesalers at a lower cost, primarily in Greece and the U.K. and sell to other European wholesalers. Our capital efficient business model is based on infrastructure, efficiency and scale.

We conduct direct distribution and sales of pharmaceuticals, medical devices, ~~generic~~branded pharmaceuticals and OTC ~~products through our subsidiary, Cosmofarm S.A.~~products. Our distribution network exceeds over 1,500 pharmacies in Greece. We have created an upgraded and high-end distribution center in Greece due to our Robotic systems and integrated automations ~~(ROWA~~(“ROWA” robotics).

We have created and developed our own proprietary branded nutraceutical products, named “Sky Premium ~~Life”~~Life®” which was launched in 2018. ~~Our~~We have a full portfolio ~~includes~~of fast moving and specialty formulas with at least 6775 product codes including vitamins, minerals and other herbal extracts. We expect to reach the number of 71150 product codes by the end of ~~2021.~~2022. Our nutraceutical products are manufactured exclusively by Doc Pharma, ~~S.A.,~~ a related party of the Company. Our nutraceutical products have penetrated ~~the UK, Germany and China~~several markets within 2021 ~~and increased our~~through digital channels such as Amazon and ~~Tmall (B2C).~~Tmall.

We focus on nutraceutical products because we foresee it as a relatively under-penetrated market throughout Europe with potential of high growth opportunities due to its large market size and margin contribution as the demand for nutraceutical products is increasing globally.

We are engaged in the promotion, distribution and sale of ~~generic~~branded pharmaceutical products throughout Europe. Through ~~our~~a related company ~~Doc Pharma,~~, we have the distribution rights to over ~~47 generic licenses of~~70 fast-moving pharmaceutical products. There is a significant growth on opportunities through product ~~codes.~~additions and geographic expansion

Our subsidiaries’ licenses help us establish and enhance our market share. SkyPharm received its Authorization for the Wholesale Distribution of Medical Products for humans use on July 22, 2015, from the Hellenic Republic National Organization for Medicines in accordance with Law 1316/1983, and the inspection by the National Organization for Medicines dated July 16, 2015 in accordance with the Guidelines 2013/C31/01. The license is valid for five years and expires on July 22, 2020. Pursuant to the EU directive of (2013/C 343/01), the Company is subject to fulfill the Guidelines of the Good Distribution Practices of medical products for human use. The Company submitted its application for renewal one month before the license expiration to the Hellenic Republic National Organization, but according to the EMA (eudragmdp.ema.europa.eu/inspections/view/wda/WDAHomePage.xhtml): “Due to the restrictions caused by COVID-19, the period of validity of MIA’s, WDA’s, GMP and GDP certificates is automatically extended until the end of 2021. On-site inspections will resume as soon as there is a consensus that the period of the public health crisis has passed. The clarifying remark section of individual MIA’s, WDA’s, GMP and GDP certificates will indicate any exceptions. Competent authorities reserve the right to inspect a manufacturing site should the need arise.” ~~Therefore, the Company is eligible to continue its operations until at least the end of 2021 and expects to receive a temporary license by the end of 2021.~~

Our subsidiary, Decahedron, was granted the license for the wholesale of medicinal products for human use in February 2021 pursuant to the regulation of 18 of The Human Medicines Regulations 2012 (SI 2012/1916). It fulfills the guidelines of the Wholesale Distribution Authorisation (Human). Finally, our subsidiary, Cosmofarm S.A., was granted the license for the wholesale of pharmaceutical products for human use on February 2019 pursuant to the EU directive of (2013/C 343/01). It fulfils the Guidelines of the Good Distribution Practices of medical products for human use. All licenses were granted based on inspections and are valid unless current inspections occur which will revise their status.

The Company uses a differentiated operating model based on a lean, nimble and decentralized structure, an emphasis on low-risk license acquisition, as well as research & development and our ability to be better owners of pharmaceutical assets than others. This operating model and the execution of our Corporate Strategy are enabling the Company to achieve sustainable growth and create shareholder value.

We are currently focusing our existing operations on expanding the business of our subsidiaries. Our operating model and the execution of our corporate strategy are designed to enable the Company to achieve sustainable growth and create shareholder value.

Supply chain disruption is a growing concern for the European pharmaceutical industry as it increasingly looks to cut costs by relying on ‘emerging markets’, where standards can be lower in terms of compliance, ethics and health and safety.

Hikes in the price of medicine and their impact on the sustainability of the healthcare systems are garnering more and more attention. European regulators are willing to play their part in safeguarding continued access to safe and effective medicines. Regulators can speed up the approval of ~~generics~~branded pharmaceuticals and biosimilars to boost competition and drive down prices.

Cuts in healthcare spending keep occurring since the financial crises of the late of 2000s. Europe’s slow recovery has been uneven, with austerity and economic uncertainty, especially in the EU’s poorer member states, such as Greece.

The World Health Organization ~~(WHO)~~(“WHO”) declared the coronavirus outbreak a pandemic on March 11, 2020. Since the outbreak in China in December 2019, COVID-19 has expanded its impact to Europe, where all of our operations reside as well as our employees, suppliers and customers. To date, our operations have been adversely affected by the following ~~Covid-19~~COVID-19 risks:

Management believes that there could be a positive long-term outcome from ~~Covid-19,~~COVID-19, which could result in an increase in sales of OTC branded products, nutraceuticals, antibacterial products, gloves, oximeters, thermometers and medical masks. However, there is no guarantee of such results. Therefore, we will increase R&D as we are aiming to innovate and create new products in order to help combat against ~~Covid-19.~~COVID-19. We have adapted our strategy in response to ~~Covid-19~~COVID-19 and will continue to do so, since we are expecting the impact of ~~Covid-19~~COVID-19 to continue for the next ~~18-24~~12 months.

What Effect Will ~~Covid-19~~COVID-19 Have on the Company’s Disclosure Controls

Management does not believe COVID-19 will have a significant effect on our disclosure controls as there have been no changes to date. Our operations have continued at a normal pace, at least ~~90%~~95% of our staff continue to work on site and those staff who are working remotely have no impact on our disclosure controls.

Three ~~and Six-Months~~Months Period Ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~

The Company had revenue of ~~$14,846,925~~$13,071,800 and ~~$12,819,972~~$11,619,076 (an increase of ~~15.81%~~12.5%) for the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020, respectively, and $26,466,001 and $24,753,220 (an increase of 6.92%) for the six months ended June 30, 2021 and 2020,~~ respectively. ~~This~~The increase in the 3-month period is mainly due to the organic growth attributed to our subsidiary, Cosmofarm, which continued the expansion and sales programs inat the local ~~level. In addition, there was an~~level, and to the significantly higher sales volume of SkyPharm, due to the increased demand ~~during this quarter~~ for ~~our~~its own ~~brand~~branded nutritional supplements named (“Sky Premium Life^®”), which resulted in achieving $524,000 more in sales compared to Q1 2021 (an increase of ~~nutraceuticals; “Sky Premium Life” and full-line wholesale. Our subsidiary, Skypharm, was focused this quarter on the sales of “Sky Premium Life” products.~~49.29%). The Company had a net ~~loss~~income of ~~$2,379,056~~$203,347 on revenue ~~$14,846,925~~of $13,071,800 versus a net ~~profit~~loss of ~~$1,377,311~~$2,173,903 on revenue ~~$12,819,972~~of $11,619,076 for the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020, respectively. The Company had a net loss of $4,552,959 on revenue of $26,466,001 versus a net income of $894,001 on revenue of $24,753,220 for the six months ended June 30, 2021 and 2020,~~ respectively.

The Company had costs of goods sold of ~~$12,810,082~~$11,179,868 versus ~~$10,471,841~~$10,617,741 (an increase of ~~22.33%~~5.29%) for the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively. ~~In addition,~~The increase in the ~~Company had~~3-month is primarily due to the increase in revenue. However, the costs of goods sold ~~of $23,427,823 versus $21,211,918 (an~~were increased by just 5.29% compared to a revenue increase of 10.45%) for the six months ended June 30, 2021 and 2020, respectively. This increase is in line with the revenue increase due to higher demand of “Sky Premium Life” nutraceutical products and the full-line wholesale. However, the increase of the cost of goods sold is disproportionate to the revenue increase12.5%, due to the ~~fact that~~higher dependence of the ~~increase of full-line~~Company on the nutraceuticals’ revenue stream, which historically achieves higher margins than the wholesale ~~products have low margins in comparison to nutraceutical products.~~one.

Our future revenue growth is expected to continue to be affected by various factors such as industry growth trends, including drug utilization, the introduction of new innovative brand therapies, the likely increase in the number of ~~generic drugs~~branded pharmaceutical products that will be available over the next few ~~years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers and the rate of conversion from brand products to those generic drugs,~~years’ price increases and price deflation, general economic conditions, including the effects of the current conflict in the Ukraine, the coronavirus in the member states of European Union, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third party reimbursement rates to our customers, and changes in government rules and regulations.

The Company had gross profit of ~~$2,036,843~~$1,891,932 versus ~~$2,348,131 (a decrease~~$1,001,335 (an increase of ~~13.26%~~88.94%) for the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020, respectively. In addition, the Company had gross profit of $3,038,178 versus $3,541,302 (a decrease of 14.21%) for the six months ended June 30, 2021 and 2020,~~ respectively. The ~~decrease~~increase in gross profit for the 3-month period is attributable to the revenue increase in conjunction with the higher gross profit margins achieved due to ~~a disproportionate~~the significant increase in ~~demand for full line wholesale and nutraceutical products and the increase of COGS.~~nutraceuticals revenue stream.

The Company had general and administrative costs of ~~$3,165,268~~$868,639 and ~~$870,704,~~$1,688,712, salaries and wages expenses of $521,471 and $531,556, sales and marketing expenses of ~~$139,633~~$146,949 and ~~$380,326~~$405,092 and depreciation and amortization expense of ~~$108,413~~$112,622 and ~~$110,788~~$107,073 for ~~a net operating loss of $1,376,470 and~~ a net operating income of ~~$986,313 (a decrease~~$242,251 and loss of ~~239.58%~~$1,731,098 (an increase of 114%) for the three months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~ respectively. The decrease in operating expenses is primarily ~~a result of~~attributed to the ~~increase in~~ stock-based compensation related to a consulting agreement entered into in February 2021 and included in the general and administrative expenses for the period ended March 31, 2021, as well as ~~an increase~~the significant decrease in ~~legal, consulting and outsourced accounting costs in the current year.~~

~~The Company had general and administrative costs of $5,385,535 and $1,684,573,~~ sales and marketing expenses of $544,725 and $434,056 and depreciation and amortization expense of $215,486 and $210,796 for a net operating loss of $3,107,568 and a net operating income of $1,211,877 (a decrease of 356.43%) for the six months ended June 30, 2021 and 2020 respectively. The increase in expenses is mainly due to the stock-based compensation ($3,157,451) consulting agreement entered into during the six months ended June 30, 2021.approximately 64%.

The Company’s other income (expense) was primarily comprised of interest expense related to notes payable and convertible notes payable ~~$780,608~~$584,176 versus ~~$651,867,~~$731,826, non-cash interest expense related to the amortization of debt discount of ~~$88,979~~$260,527 versus ~~$0, a loss on equity investments of $161 versus gain of $32,418,~~$50,109, a gain on extinguishment of debt of ~~$0 versus $779,224~~$1,004,124 due to ~~an amended~~a debt ~~exchange agreement dated as~~extension that took place on March 3^rd, 2022 versus a gain of ~~February 5, 2021,~~$445,636, a change in fair value of derivative liability of ~~$26,496~~$15,001 versus $0$61,373 due to agreements on convertible debentures, interest income of $64,827 versus $0 and a foreign currency loss of $159,352 versus a gain of ~~$96,584 versus of $194,828~~$306,020 for the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively. Also, The Company’s other expense was ~~$39,415~~$54,812 versus other ~~income~~expense of ~~$39,383~~$178,211 for the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020, respectively.~~

The Company’s other income (expense) was primarily comprised of interest expense related to notes payable and convertible notes payable $,1,512,433 versus $1,063,988, non-cash interest expense related to the amortization of debt discount of $139,088 versus $29,509, a gain on equity investments of $279 versus $10,246, a gain on extinguishment of debt of $445,636 versus $779,224 due to an amended debt exchange agreement dated as of February 5, 2021, a change in fair value of derivative liability of $87,869 versus $0 due to agreements on convertible debentures, and a foreign currency loss of $209,436 versus a loss of $32,306 for the six months ended June 30, 2021 and 2020, respectively. Also, The Company’s other expense was $217,626 versus other income of $27,949 for the six-months ended June 30, 2021 and 2020, respectively.

The Company had an unrealized foreign currency ~~gain~~loss of ~~$284~~$405,229 versus a ~~gain~~loss of ~~$182,840~~$473,578 and a net comprehensive loss of ~~$2,378,772~~$5,990,375 versus ~~profit~~loss of ~~$1,560,151~~$2,647,481 for the three months ended ~~June 30,~~March 31, 2022 and 2021, and 2020, respectively. The Company had an unrealized foreign currency loss of $473,294 versus gain of $39,078 and a net comprehensive loss of $5,026,253 versus profit of $933,079 for the six months ended June 30, 2021 and 2020, respectively.

As of ~~June 30, 2021,~~March 31, 2022, the Company had working capital of ~~$10,417,725~~$11,831,133 compared to ~~$5,979,870~~$10,950,492 as of December 31, ~~2020.~~2021.

The Company had cash of ~~$805,772~~$1,010,427 versus ~~$628,395~~$286,487 as of ~~June 30, 2021~~March 31, 2022 and December ~~2020,~~2021, respectively. The Company had net cash used in operating activities of ~~$2,519,394~~$2,337,276 and ~~$5,876,080~~$665,339 for the ~~six~~three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively. The Company has devoted substantially all of its cash resources to expand through organic business growth ~~and, where appropriate, through the execution of selective company acquisitions,~~ and has incurred significant general and administrative expenses in order to enable the financing and growth of its business and operations.

The Company had net cash provided by investing activities of $94,550 and net cash used in investing activities of ~~$12,100 and $86,378~~$2,310 during the ~~six~~three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively. For the ~~six~~three months ended ~~June 30, 2021 and 2021 this~~March 31, 2022 the net cash provided by investing activities was ~~due~~mainly attributable to the ~~purchase of fixed assets.~~proceeds from the loan receivable from a third party.

The Company had net cash provided by financing activities of ~~$2,724,871~~$2,914,441 versus ~~$8,301,764~~$380,118 during the ~~six~~three months ended ~~June 30,~~March 31, 2022 and 2021, respectively. The net cash increase in the 3-month period ended om March 31, 2022 is mainly attributable to the net proceeds of $5,452,300 of the preferred stock offering on February 28, 2022 less the payments made for the loans and ~~2020, respectively.~~notes payable.

For the ~~quarter~~period ended ~~June 30, 2021,~~March 31, 2022, the Company also received proceeds from lines of credit of ~~$12,311,882~~$5,779,114 and payments of lines of credit of ~~$12,189,057,~~$6,244,162, for a net decrease on the line of credit of ~~$122,825.~~$465,048.

We anticipate using cash in our bank account as of ~~June 30, 2021,~~March 31, 2022, cash generated ~~from the operations of the Company and its operating subsidiaries and~~ from debt or equity financing, from investing activities or from ~~a loan from~~ management loans, to the extent that funds are available to do so to conduct our business in the upcoming year. Management is not obligated to provide these or any other funds. If we fail to meet these requirements, we may lose the qualification for quotation and our securities would no longer trade on the over-the-counter markets. Further, as a consequence we would fail to satisfy our reporting obligations with the Securities and Exchange Commission (“SEC”), and investors would then own stock in a company that does not provide the disclosure available in quarterly and annual reports filed with the SEC and investors may have increased difficulty in selling their stock as we will be non-reporting.

We assess the foreseeable development of the Company as being positive. Over the medium term we expect to further expand our market shares. However, during the course of further organizational optimization there may be associated extraordinary additional costs.

Our plan for our own branded nutraceuticals is to enlarge our portfolio up to 150 SKUs by the end of 2022 including more basic line formulas to cover more customer needs of any age, advanced formulations, formulas based on herbs and further clinical studies with R&D for further products. Our plan for geographic expansion in distributing and market penetration in EU, Asia, USA, and Canada is based on exclusive distributors, wholesalers, ecommerce, development of franchising model, alliances and acquisitions of nutraceutical companies.

The pharmaceutical industry is a dynamic industry full of challenges. The fast-changing environment requires our company to have effective strategic planning and monitoring in order to be responsive and adaptable to such challenges.

Our multi-targeted approach is trying to mitigate obstacles by setting out an objective evaluation of the organization’s goals. We set achievable future targets based on past performance, segments and drivers. In addition, weour plan for branded pharmaceuticals is geographic expansion across the world, especially in EU and ~~model different scenarios and assess the impact of later strategic decisions on the business in both short and long term.~~

~~We are planning to develop and expand our business organically by securing new clients,~~UK, as well as ~~expanding the amount of business we do~~in third countries with ~~our existing clients. Our resources, industry knowledge, skills, equipment~~fast registration and ~~long-term relationships~~developed markets with ~~clients provide us the opportunity to focus on the increase of our distribution channels. In addition, our organic growth will be driven by distributing more profitable pharmaceutical products,~~liberalized OTC ~~medicines,~~policies for online pharmacies and ~~nutraceuticals. We are committed to capitalizing on sales growth opportunities by expanding our customer pipeline across the European market, as well as entering markets outside the European Union.~~

supermarkets. We also intend to ~~acquire additional companies that are operating~~enhance our exclusive distribution rights with a growing basis of cooperating partners whilst purchasing generics’, biosimilar drugs and OTC licenses. We also intend to enhance our product expectance by registered copyrights and trademarks in all OTC drugs. In addition, it remains committed to strategic research and development across each business unit with a particular focus on assets with inherently lower risk Our plan for our full line wholesale is to expand in the ~~pharmaceutical industry~~Greek territory, enlarge our customer portfolio and integrate of established sales network of pharmacies through the use of B2B and B2C ecommerce platforms and exclusive distributors. We are also aiming in increasing the exports of branded pharmaceuticals as we focus on higher profit margins categories (OTC and VMS), deliver 3PL services to pharma companies, put in force loyalty programs, provide added value services to pharmacies and emergency deliveries to VIP customers. The Company will evaluate and, where appropriate, execute on opportunities to expand its network of pharmacies and products in areas that it believes will offer above average growth characteristics and attractive margins.

The Company is growing its business through organic growth, market penetration, geographic expansion and acquisitions which would add value to ~~our Company~~its business and its ~~shareholders giving us~~Shareholders. The Company is also committed to pursuing various forms of business development; this can include trading, alliances, joint ventures and dispositions. Moreover, it hopes to continue to build on its portfolio of pharmaceutical products and expand its OTC and nutraceutical product portfolio. Thus, the ~~opportunity~~Company is developing a sound sales distribution network specializing in its own branded nutraceutical products.

The Company’s main objective is expanding the business operations of its subsidiaries by concentrating its efforts on becoming an international pharmaceutical Company. The Company views its business development activity as an enabler of its strategies, and it seeks to ~~penetrate into new markets~~generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic, and financial approach to evaluating business development opportunities. Under these principles the Company assesses businesses and assets as part of its regular, ongoing portfolio review process and continues to consider trading development activities for its businesses. The Company’s objective is the optimization of operating expenses across all entities without compromising the quality of the Company’s services and products.

~~The Company intends to expand~~Changes in the behavior and ~~enhance~~spending patterns of purchasers of pharmaceutical and healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the ~~sales~~frequency of ~~its own branded nutraceutical products, “Sky Premium Life”, through digital channels across Europe. Also, the plan for the next twelve months is to penetrate into the UK market~~doctor visits, and utilize the current distribution channel of its UK subsidiary, Decahedron. The existing portfolio of our own branded nutraceutical products reached the number of 67 SGUs as of today and the Company plans to increase it to 150 SGUs within the next twelve months.

~~We intend to expand our business within the generic pharmaceutical products market and obtain more exclusive distribution rights in Europe. These industries are highly competitive and~~foregoing healthcare insurance coverage, may ~~significantly affect~~impact the Company’s sales of these products, including, but not limited to, price and cost-effectiveness, marketing effectiveness, product labeling, quality control and quality assurance. Through our related party, Doc Pharma which is the owner of 47 plus generic licenses of fast-moving product codes we will use innovative products distribution.business.

We intend to develop platforms for Business-to-Business and Business-to-Customers transactions. We expect our relationships with our customers and suppliers to be redefined, our supply chain management to be improved and our customers loyalty to be increased, as a result, improved sales. We hope the platforms will lead to lower costs and errors avoidance through the automated process.

The Company acquired within current quarter one more robotic system for fast move items which will essentially result in cost savings, time efficiency, errors avoidance and effectiveness. This is expected to lead us to increased productivity, minimization of delivery time by 2/3, improved safety and make our subsidiary, Cosmofarm S.A., one of the leaders in pharmaceutical products distribution.

The pharmaceutical sector offers a large growth potential within the European pharmaceutical market, if service, price and quality are strictly directed towards the customer requirements. WeThe Company will continue to encounter ~~the~~ competition in the market by product, service, reliability, and a high level of quality. On the procurement side, wethe Company can access a wide range of supply possibilities. To minimize business risks, ~~we diversify our~~the Company diversifies its sources of supply all over Europe. ~~We secure our~~It secures its high-quality demands through careful supplier qualification and selection, as well as active suppliers’ system management.

~~We assess~~While the ~~foreseeable development~~Company intends to pursue these milestones, there may be circumstances where for valid business reasons or due to factors beyond the control of the Company ~~as being positive. Over~~(e.g., the ~~medium term we assume~~COVID-19 pandemic), a reallocation of efforts may be necessary or advisable. Although the Company does not currently anticipate that wethe COVID-19 pandemic will cause material delays in the timelines or estimates set out above, due to the evolving nature of COVID-19 and its impacts, these timelines and estimates may require adjustment in the future.

The Company intends to spend the funds available to it in working capital, inventories, intangible assets, acquisitions, R&D, sales and marketing expenses. Due to the uncertain nature of the industry in which the Company will operate, projects may be frequently reviewed and reassessed. Accordingly, while it is currently intended by management that the available funds will be ~~able to further expand our market shares. However, during the course of further organizational optimization there~~expended as set forth above, actual expenditures may ~~be associated extraordinary additional costs.~~in fact differ from these amounts and allocations.

As of ~~June 30, 2021,~~March 31, 2022, there were no off-balance sheet arrangements.

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” under the Management’s Discussion and Analysis section. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Revenue Recognition: The Company adopted Topic 606 Revenue from Contracts with Customers on January 1, 2018. As a result, it has changed its accounting policy for revenue recognition as detailed above.

Foreign Currency. Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in net (loss) earnings.

Income Taxes. The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes, ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company is liable for income taxes in Greece and the United Kingdom. The corporate income tax rate is 22% in Greece (tax losses are carried forward for five years effective January 1, 2013) and 19% in United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership.

We recognize the impact of an uncertain tax position in our financial statements if, in management’s judgment, the position is not more-likely-then-not sustainable upon audit based on the position’s technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position is necessary. We operate and are subject to audit in multiple taxing jurisdictions.

We record interest and penalties related to income taxes as a component of interest and other expense, respectively.

Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740 “Accounting for Income Taxes” as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in this financial statement because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

The Company has net operating loss carry-forwards in our parent, Cosmos Holdings Inc., which are applicable to future taxable income in the United States (if any). Additionally, the Company has income tax liabilities in the United Kingdom. The income tax assets and liabilities are not able to be netted. We therefore reserve the income tax assets applicable to the United States but recognize the income tax liabilities in Greece and the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership.

Not applicable. A smaller reporting company is not required to provide the information required by this Item.

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act) that are designed to ensure that information required to be disclosed in the Company’s Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive ~~Officer/~~Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

The Company’s management, with the participation of the Company’s Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the Principal Executive Officer and the Principal Financial Officer have concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were partially effective. The ~~Internal Auditor~~Management is committed to remediate the material weaknesses identified in the Form 10K, which include lack of ~~the Company has already developed~~segregation of duties and ~~remediated some~~lack of ~~the existing~~ internal controls ~~and processes. The Company~~structure review. As part of this commitment, the Management has hired ~~one more person to join~~additional individuals in the ~~internal audit~~finance team ~~within current quarter~~ in order to ~~empower the reassurance of regulatory compliance with SEC reporting requirements.~~

The Company has increased its personnel resources in order to eliminate the material weaknesses which have been identified so far. The Company has hired an Internal Auditor Assistant in order to remediate and strengthen existing procedures,assign responsibilities on key processes, examine and improve operating practices, perform extensive financial control and financial risk management processes, as well as to define and develop new policies and controls in order to improve the accuracy of the disclosures.

~~We have appointed a new member on board within~~ In addition, the ~~fiscal year ending December 31, 2021~~Internal Auditors of the Company are in ~~order to advise and help us~~the process of developing further procedures to ensure the ~~completeness, integrity, reliability and accuracy~~effectiveness of ~~our systems,~~internal controls and ~~procedures.~~the accuracy and completeness of financial reporting. The Company will evaluate the controls and procedures on a quarterly basis and judge what weaknesses to be remediated based on materiality and circumstances.

During the most recently completed fiscal year, there has been no change in our internal control over financial reporting that has materially affected or is reasonably likely to materially affect it.

. Our ~~existing~~ Audit Committee is in process of evaluating our existing controls and procedures, whilst communicating with the Management on quarterly basis. ~~We are in process of appointing Nominate and Compensation Committees and preparing the relevant procedures and charters.~~

We have a separately-designated standing audit committee, which is appointed by the Board of Directors of Cosmos Holdings Inc. On April 28, 2022, Dr Anastasios Aslidis was elected to serve the Board of Directors and was appointed as a member of the Audit Committee, replacing Mr Peter Goldstein, who submitted his resignation on the same date. Our three independent directors, Anastasios Aslidis, John Hoidas and Demetrios Demetriades ~~and Peter Goldstein~~ serve on the Audit Committee. Primary function of the committee is to assist the Board of Directors in overseeing (1) the financial reporting and accounting processes of the Company, and (2) the financial statements audits of the Company. The Committee also prepares a written report to be included in the annual proxy statement of the Company pursuant to the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”). In furtherance of these purposes, the Committee shall maintain direct communication among the Company’s independent auditors and the Board of Directors. The independent auditors and any other registered public accounting firm engaged in preparing or issuing an audit report or performing other audit review or attest services for the Company shall report directly to the Committee and are ultimately accountable to the Committee and the Board of Directors.

In discharging its oversight role, the Committee is authorized to investigate any matter brought to its attention with full access to all books, records, facilities and personnel of the Company. The Committee shall have the sole authority to retain at the Company’s expense outside legal, accounting or other advisors to advise the Committee and to receive appropriate funding, as determined by the Committee, from the Company for the payment of the compensation of such advisors and for the payment of ordinary administrative expenses of the Committee that are necessary to carry out its duties. The Committee may request any officer or employee of the Company or the Company’s outside counsel or independent auditors to attend a meeting of the Committee or to meet with any member of, or advisors to, the Committee. The Committee may also meet with the Company’s investment bankers or financial analysts who follow the Company.

The Committee shall meet no less frequently than four times per year, with additional meetings as circumstances warrant. The Committee shall also meet periodically with management, the internal auditors, if any, and the independent auditors in separate executive sessions. The Committee shall record the minutes of all such meetings and shall submit the minutes of its meetings to, or discuss the matters deliberated at each meeting with, the Board of Directors. The Company’s chief financial or accounting officer shall function as the management liaison officer to the Committee.

~~As previously disclosed on~~There have been no changes since the filing of the Company’s Form ~~10-Q filed on May 17, 2021, Company entered into a Debt Exchange Agreement (the “Agreement”) dated as of May 10, 2021, with Grigorios Siokas, its Chief Executive Officer. Under~~10-K for the Agreement, which was filed as Exhibit 10.1 to the Form 10-Q, Mr. Siokas agreed to forego repayment of $600,000 of indebtedness owed to him by the Company pursuant to a September 18, 2020 Settlement of a Section 16(b) lawsuit. Mr. Siokas settled the lawsuit in an effort to avoid the uncertainty of litigation and further legal expenses. During the quarteryear ended ~~June 30, 2021, the Company received $600,000 of additional paid-in-capital and decreased the related party loan by $600,000.~~December 31, 2021.

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Nevada		27-0611758
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

141 West Jackson Blvd, Suite 4236 Chicago, Illinois		60604
(Address of principal executive offices)		(Zip Code)

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated ~~filer~~Filer	☐	Smaller reporting company	☒
(Do not check if a smaller reporting company)		Emerging growth company	☐

PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited).	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	3835

Item 3.	Quantitative and Qualitative Disclosures about Market Risk.	4543

Item 4.	Controls and Procedures.	4543

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings.	4745

Item 1A	Risk Factors	4745

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	4745

Item 3.	Defaults Upon Senior Securities.	4745

Item 4.	Mine Safety Disclosures.	4745

Item 5.	Other Information.	4745

Item 6.	Exhibits.	4846

SIGNATURES		4947

COSMOS HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2021			December 31, 2020
	(Unaudited)
ASSETS

CURRENT ASSETS:
Cash and cash equivalents	$	805,772		$	628,395
Accounts receivable, net		25,544,240			23,440,650
Accounts receivable - related party		3,135,184			3,468,564
Marketable securities		216,107			222,792
Inventory		3,530,874			3,292,557
Prepaid expenses and other current assets		4,931,366			5,148,441
Prepaid expenses and other current assets - related party		2,917,334			3,468,653
Operating lease right-of-use asset		983,849			833,763
Financing lease right-of-use asset		250,534			269,131

TOTAL CURRENT ASSETS		42,315,260			40,772,946

Property and equipment, net		1,578,041			1,757,213
Goodwill and intangible assets, net		214,099			230,506
Other assets		763,645			905,318
Deferred tax assets		286,329			178,430

TOTAL ASSETS	$	45,157,374		$	43,844,413

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	12,449,944		$	11,973,981
Accounts payable and accrued expenses - related party		193,894			1,733
Accrued interest		953,625			742,374
Customer advances		19,378			22,340
Convertible notes payable, net of unamortized discount of $418,504 and $494,973, respectively		766,496			952,027
Derivative liability - convertible note		435,478			460,728
Notes payable		9,335,709			12,042,712
Notes payable - related party		486,005			501,675
Lines of credit		5,038,912			5,076,684
Loans payable - related party		704,403			1,629,246
Taxes payable		764,140			760,446
Operating lease liability, current portion		168,216			200,204
Financing lease liability, current portion		80,891			89,926
Other current liabilities		500,444			339,000

TOTAL CURRENT LIABILITIES		31,897,535			34,793,076

Share settled debt obligation		1,554,590			1,554,590
Notes payable - long term portion		10,235,503			10,771,882
Operating lease liability, net of current portion		801,243			590,538
Financing lease liability, net of current portion		180,134			188,172
Other liabilities		103,821			107,168
TOTAL LIABILITIES		44,772,826			48,005,426

Commitments and Contingencies (see Note 13)		0			0

STOCKHOLDERS' EQUITY (DEFICIT):
Preferred stock, $0.001 par value; 100,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2021 and December 31, 2020		0			0
Common stock, $0.001 par value; 300,000,000 shares authorized; 16,566,947 and 13,485,128 shares issued and 16,216,619 and 13,069,800 outstanding as of June 30, 2021 and December 31, 2020, respectively		16,566			13,484
Additional paid-in capital		23,901,367			14,333,285
Treasury stock, 350,328 and 415,328 shares as of June 30, 2021 and December 31, 2020, respectively		(611,204	)		(611,854	)
Accumulated deficit		(23,303,783	)		(18,750,824	)
Accumulated other comprehensive income		381,602			854,896

TOTAL STOCKHOLDERS' EQUITY (DEFICIT)		384,548			(4,161,013	)

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$	45,157,374		$	43,844,413

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

	March 31, 2022			December 31, 2021
	(Unaudited)
ASSETS

CURRENT ASSETS:
Cash and cash equivalents	$	1,010,427		$	286,487
Accounts receivable, net		26,094,450			26,858,114
Accounts receivable - related party		2,844,572			2,901,300
Marketable securities		12,551			11,468
Inventory		4,007,977			3,147,276
Loans receivable		375,195			377,590
Prepaid expenses and other current assets		1,944,720			2,987,687
Prepaid expenses and other current assets - related party		4,368,794			3,263,241
Operating lease right-of-use asset		775,545			834,468
Financing lease right-of-use asset		192,822			211,099

TOTAL CURRENT ASSETS		41,627,053			40,878,730

Property and equipment, net		1,777,889			1,888,052
Goodwill and intangible assets, net		464,630			485,767
Loans receivable - long term portion		4,227,268			4,410,689
Other assets		909,581			915,250
Deferred tax assets		767,267			850,774

TOTAL ASSETS	$	49,773,688		$	49,429,262

LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	11,781,189		$	12,126,626
Accounts payable and accrued expenses - related party		220,887			599,125
Accrued interest		1,033,866			1,019,889
Lines of credit		4,362,327			4,743,557
Convertible notes payable, net of unamortized discount of $191,085 and $258,938, respectively		448,915			381,062
Derivative liability - convertible note		30,664			45,665
Notes payable		6,143,075			5,462,504
Notes payable - related party		455,035			464,264
Loans payable		1,000,000			1,000,000
Loans payable - related party		1,703,881			1,293,472
Taxes payable		1,192,178			1,324,722
Operating lease liability, current portion		158,359			138,450
Financing lease liability, current portion		71,861			73,078
Other current liabilities		1,193,683			1,255,824

TOTAL CURRENT LIABILITIES		29,795,920			29,928,238

Share settled debt obligation		1,554,590			1,554,590
Lines of credit - long-term portion		185,872			366,171
Notes payable - long term portion		6,885,806			12,356,384
Operating lease liability, net of current portion		617,183			696,015
Financing lease liability, net of current portion		131,016			148,401

TOTAL LIABILITIES		39,170,387			45,049,799

Commitments and Contingencies (see Note 14)		0			0

MEZZANINE EQUITY
Preferred stock, $0.001 par value; 100,000,000 shares authorized:
Series A preferred stock, stated value $1,000 per share, 6,000,000 shares authorized; 6,000 and 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021; liquidation preference of $6,000,000 and $0, respectively		5,452,300			0

STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 300,000,000 shares authorized; 18,611,980 and 17,544,509 shares issued and 18,224,556 and 17,157,085 outstanding as of March 31, 2022 and December 31, 2021, respectively		18,611			17,544
Additional paid-in capital		40,648,106			39,675,753
Treasury stock, 387,424 and 387,424 shares as of March 31, 2022 and December 31, 2021		(816,707	)		(816,707	)
Accumulated deficit		(34,142,159	)		(34,345,506	)
Accumulated other comprehensive loss		(556,850	)		(151,621	)

TOTAL STOCKHOLDERS' EQUITY		5,151,001			4,379,463

TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY	$	49,773,688		$	49,429,262

COSMOS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020


REVENUE	$	14,846,925		$	12,819,972		$	26,466,001		$	24,753,220

COST OF GOODS SOLD		12,810,082			10,471,841			23,427,823			21,211,918

GROSS PROFIT		2,036,843			2,348,131			3,038,178			3,541,302

OPERATING EXPENSES
General and administrative expenses		3,165,268			870,704			5,385,536			1,684,573
Sales and marketing expenses		139,633			380,326			544,725			434,056
Depreciation and amortization expense		108,413			110,788			215,486			210,796
TOTAL OPERATING EXPENSES		3,413,314			1,361,818			6,145,747			2,329,425

INCOME (LOSS) FROM OPERATIONS		(1,376,471	)		986,313			(3,107,569	)		1,211,877

OTHER INCOME (EXPENSE)
Other expense, net		(39,415	)		39,383			(217,626	)		27,949
Interest income (expense)		(780,607	)		(651,867	)		(1,512,433	)		(1,063,988	)
Non-cash interest expense		(88,979	)		0			(139,088	)		(29,509	)
Gain (loss) on equity investments, net		(161	)		32,418			279			10,246
Gain on extinguishment of debt		0			779,224			445,636			779,224
Change in fair value of derivative liability		26,496			0			87,869			0
Foreign currency transaction, net		96,584			194,828			(209,436	)		(32,306	)
TOTAL OTHER INCOME (EXPENSE), NET		(786,082	)		393,986			(1,544,799	)		(308,384	)

LOSS BEFORE INCOME TAXES		(2,162,553	)		1,380,299			(4,652,368	)		903,493

BENEFIT FROM (PROVISION FOR) INCOME TAXES		(216,503	)		(2,988	)		99,409			(9,492	)

NET INCOME (LOSS)		(2,379,056	)		1,377,311			(4,552,959	)		894,001

OTHER COMPREHENSIVE INCOME(LOSS)
Foreign currency translation adjustment, net		284			182,840			(473,294	)		39,078

TOTAL COMPREHENSIVE INCOME (LOSS)	$	(2,378,772	)	$	1,560,151		$	(5,026,253	)	$	933,079

BASIC NET INCOME (LOSS) PER SHARE	$	(0.15	)	$	0.10		$	(0.29	)	$	0.07
DILUTED NET INCOME (LOSS) PER SHARE	$	(0.15	)	$	0.10		$	(0.29	)	$	0.07

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
Basic		16,105,409			13,225,387			15,572,773			13,225,387
Diluted		16,105,409			13,254,116			15,572,773			13,254,953

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

	Three Months Ended March 31,
	2022			2021

REVENUE	$	13,071,800		$	11,619,076

COST OF GOODS SOLD		11,179,868			10,617,741

GROSS PROFIT		1,891,932			1,001,335

OPERATING EXPENSES
General and administrative expenses		868,639			1,688,712
Salaries and wages		521,471			531,556
Sales and marketing expenses		146,949			405,092
Depreciation and amortization expense		112,622			107,073
TOTAL OPERATING EXPENSES		1,649,681			2,732,433

INCOME (LOSS) FROM OPERATIONS		242,251			(1,731,098	)

OTHER INCOME (EXPENSE)
Other expense, net		(54,812	)		(178,211	)
Interest expense		(584,176	)		(731,826	)
Interest income		64,827			0
Non-cash interest expense		(260,527	)		(50,109	)
Gain on equity investments, net		1,678			440
Gain on extinguishment of debt		1,004,124			445,636
Change in fair value of derivative liability		15,001			61,373
Foreign currency transaction, net		(159,352	)		(306,020	)
TOTAL OTHER INCOME (EXPENSE), NET		26,763			(758,717	)

INCOME (LOSS) BEFORE INCOME TAXES		269,014			(2,489,815	)

BENEFIT FROM (PROVISION FOR) INCOME TAXES		(65,667	)		315,912

NET INCOME (LOSS)		203,347			(2,173,903	)

Deemed dividend on warrants		(5,788,493	)		0

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS		(5,585,146	)		(2,173,903	)

OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustment, net		(405,229	)		(473,578	)

TOTAL COMPREHENSIVE LOSS	$	(5,990,375	)	$	(2,647,481	)

BASIC NET LOSS PER SHARE	$	(0.31	)	$	(0.14	)
DILUTED NET LOSS PER SHARE	$	(0.31	)	$	(0.14	)

Basic		17,755,516			15,034,219
Diluted		17,755,516			15,034,219

COSMOS HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

																Accumulated
																Other
	Common Stock				Additional		Treasury Stock									Comprehensive			Total
	No. of Shares		Value		Paid-in Capital		No. of Shares			Value			Accumulated Deficit			Income (Loss)			Stockholders' Deficit

Balance at January 1, 2020		13,225,387	$	13,225	$	13,525,749		(365,328	)	$	(411,854	)	$	(19,571,610	)	$	(16,339	)	$	(6,460,829	)
Foreign currency translation adjustment, net		-		0		0		-			0			0			(143,762	)		(143,762	)
Net loss		-		0		0		-			0			(483,310	)		0			(483,310	)
Balance at March 31, 2020		13,225,387	$	13,225	$	13,525,749		(365,328	)	$	(411,854	)	$	(20,054,920	)	$	(160,101	)	$	(7,087,901	)
Foreign currency translation adjustment, net		-		0		0		-			0			0			182,840			182,840
Net loss		-		0		0		-			0			1,377,311			0			1,377,311
Balance at June 30, 2020		13,225,387		13,225		13,525,749		(365,328	)		(411,854	)		(18,677,609	)		22,739			(5,527,750	)

COSMOS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Six Months Ended June 30,
	2021			2020

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(4,552,959	)	$	894,001
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:
Depreciation and amortization expense		166,219			140,748
Amortization of right-of-use assets		49,267			70,048
Amortization of debt discounts		139,088			29,509
Lease expense		99,610			104,588
Interest on finance leases		5,250			5,251
Loss on disposal of fixed asset					21,624
Stock-based compensation		3,157,450			0
Deferred income taxes		(107,646	)		0
Gain on extinguishment of debt		(445,636	)		(779,224	)
Change in fair value of the derivative liability		(87,869	)		0
Loss on change in fair value of equity investments		(1,318	)		(13,517	)
Changes in Assets and Liabilities:
Accounts receivable, net		(2,839,680	)		(5,960,027	)
Accounts receivable - related party		324,536			(53,620	)
Inventory		(336,047	)		(214,909	)
Prepaid expenses and other current assets		(1,415,455	)		(4,448,671	)
Prepaid expenses and other current assets - related party		450,454			2,914,042
Other assets		153,055			(12,084	)
Accounts payable and accrued expenses		2,249,153			2,052,075
Accounts payable and accrued expenses - related party		195,151			(237,809	)
Accrued interest		211,251			(260,347	)
Customer advances		(2,312	)		(92,751	)
Other current liabilities		161,444			49,165
Lease liabilities		(71,436	)		(84,425	)
Taxes payable		0			156
Other liabilities		(20,964	)		97
NET CASH USED IN OPERATING ACTIVITIES		(2,519,394	)		(5,876,080	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets		(12,100	)		(86,378	)
NET CASH USED IN INVESTING ACTIVITIES		(12,100	)		(86,378	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of convertible note payable		(362,000	)		(200,000	)
Proceeds from convertible note payable		100,000			0
Payment of related party note payable		0			(789,961	)
Payment of note payable		(20,000	)		(171,614	)
Proceeds from note payable		0			7,908,955
Payment of related party loan		(125,589	)		(102,257	)
Proceeds from related party loan		2,811,062			586,759
Payment of lines of credit		(12,189,057	)		(8,100,149	)
Proceeds from lines of credit		12,311,882			9,208,750
Payments of finance lease liability		(51,427	)		(38,719	)
Proceeds from sale of treasury stock		250,000			0
NET CASH PROVIDED BY FINANCING ACTIVITIES		2,724,871			8,301,764

Effect of exchange rate changes on cash		(16,000	)		28,665

NET CHANGE IN CASH		177,377			2,367,971

CASH AT BEGINNING OF PERIOD		628,395			38,537
CASH AT END OF PERIOD	$	805,772		$	2,406,508

Supplemental Disclosure of Cash Flow Information

Cash paid during the period:
Interest	$	208,565		$	124,178
Income tax	$	0		$	11,605

Supplemental Disclosure of Non-Cash Investing and Financing Activities

Conversion of notes payable to common stock	$	2,564,364		$	0

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

	Estimated Useful Life
Leasehold improvements and technical works		Lesser of lease term or 40 years
Vehicles		6 years
Machinery		20 years
Furniture, fixtures and equipment		5–10 years
Computers and software		3-5 years

	March 31, 2022			December 31, 2021

Beginning balance	$	464,264		$	501,675
Foreign currency translation		(9,229	)		(37,411	)
Ending balance	$	455,035		$	464,264

	June 30, 2021		December 31, 2020
National	$	3,093,644	$	3,540,550
Alpha		1,019,368		1,106,894
Pancretan		532,191		0
National - COVID		393,709		429,240
Total	$	5,038,912	$	5,076,684

	March 31, 2022			December 31, 2021
National	$	2,887,143		$	3,265,236
Alpha		927,008			947,333
Pancreta		417,671			489,985
National – COVID		316,377			407,174
Subtotal		4,548,199			5,109,728
Reclassification of National-COVID – Long-term		(185,872	)		(366,171	)
Ending balance	$	4,362,327		$	4,743,557

	a)	~~The Conversion Price~~. The Conversion Price shall equal the Variable Conversion Price (subject to stock splits, dividends, rights offerings or similar events) shall mean seventy-five percent (75%) multiplied by the Market Price defined as the average of the three (3) lowest trading prices for common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date.

	b)	~~Conversion upon Qualified Financing~~. If the Company engaged in a registered offering resulting in an “uplisting” to a higher-tiered trading market (a “Qualified Financing”), the Holder has the option to convert any outstanding debt due under this Note at seventy-five (75%) of the per share offering price.

	c)	~~Conversion Price During Major Announcements~~. In the event the Borrower (i) makes a public announcement that it intends to consolidate or merge with any other Company (other than a merger in which the Borrower is the surviving or continuing Company and its capital stock is unchanged or sell or transfer all or substantially all of the assets of the Borrower or (ii) any person, group or entity (including the Borrower) publicly announces a tender offer to purchase fifty percent (50%) or more of the Borrower’s Common Stock (or any other takeover scheme), then the Conversion Price shall, effective upon the announcement date shall be equal to the lower of (x) the Conversion Price which would have been applicable for a Conversion occurring on the Announcement Date and (y) the Conversion Price that would otherwise be in effect.

	~~June 30,~~ ~~2021~~
~~Dividend yield~~		0	%
~~Expected volatility~~	~~113.8%-139.0~~		%
~~Risk free interest rate~~	~~0.15%-0.18~~		%
~~Contractual terms (in years)~~	~~0.34 – 0.89~~

	March 31,			December 31,
	2022			2021
Dividend yield		0	%		0	%
Expected volatility		87.9	%	106.8%-107.3		%
Risk free interest rate		1.40	%	0.41%-0.44		%
Contractual terms (in years)		.50		.50 – .52

Our outstanding debt as of March 31, 2022 is repayable as follows:
	March 31, 2022
2022	$	4,116,483
2023		9,699,419
2024		253,694
2025		227,261
2026 and thereafter		140,923
Total debt		14,437,780
Less: fair value adjustments to assumed debt obligations		(1,408,899	)
Less: notes payable - current portion		(6,143,075	)
Notes payable - long term portion	$	6,885,806

	·	Issue on August 4, 2021, 321,300 shares of common stock to settle $1,606,500 (€1,350,000) of debt. The Company recorded a gain on settlement of $292,383 upon the issuance of the 321,300 shares

	·	Agreed to issue no more than 238,000 shares of common stock upon approval of the listing of the Company’s common stock to the Nasdaq to settle $1,190,000 (€1,000,000) of debt. The Company issued these shares on February 28, 2022. Upon issuance of the 238,000 shares of common stock, the Company recorded a gain on extinguishment of debt in the amount of $216,580 determined using the fair value of the Company’s common stock at the commitment date of $4.09 per share.

•	The Lender will provide SkyPharm a facility of up to €2,000,000 ($2,369,600) secured against SkyPharm’s receivables from the sale of branded and generic pharmaceutical sales. In the event that accounts receivable become uncollectible, the Company will be obligated to pay back the notes in full.

•	~~The total facility will be calculated as 95% of the agreed upon value of Decahedron’s receivables.~~

•	~~The term of the SkyPharm Facility will be for 12 months.~~

•	~~The obligations of SkyPharm are guaranteed by the Company pursuant to a Cross Guarantee and Indemnity Agreement.~~

•	~~The Lender has the right to make payments directly to SkyPharm’s suppliers.~~

•	~~The following fees should be paid in connection with the SkyPharm Facility:~~

	o	~~2% of the maximum principal amount as an origination fee.~~

	o	~~A one percent (1%) monthly fee.~~

	•	~~A listing of approved purchasers;~~

	•	~~To permit SkyPharm to request Synthesis to make payments under the TFF directly to SkyPharm so that SkyPharm can discharge its obligations to a commodity seller directly;~~

	•	To prohibit SkyPharm from entering into a commodity contract which grants more than seventy-five (75) days delay between the payment for products and receipt of the purchase price and placed other limitations on terms of commodity contracts;

	•	If Grigorios Siokas, CEO of Cosmos Holdings Inc. (“Cosmos”), ceases to own or control at least fifty-one (51%) percent of the shares of Cosmos, or SkyPharm ceases to be a wholly-owned subsidiary of Cosmos, either event shall constitute an Event of Default (as defined);

	•	~~The maximum aggregate amount of the TFF is €15,000,000, although there is no commitment for any future loans under the TFF;~~

	•	The interest rate on the TFF for: (i) all lending in U.S. dollars is the one-month LIBOR plus six (6%) percent margin; and (ii) for all lending in Euro, the one-month Euribor Rate plus six (6%) percent per annum, commencing June 1, 2018.

	•	~~Synthesis is permitted to terminate the TFF at any time and demand repayment of all outstanding principal and interest in full within six (6) months from the date of notification.~~

Maturity of Lease Liability
Remainder of 2021	$	51,377
2022		86,663
2023		74,113
2024		55,762
2025		24,823
Thereafter		589
Total undiscounted finance lease payments	$	293,327
Less: Imputed interest		(32,302	)
Present value of finance lease liabilities	$	261,025

Maturity of Lease Liability
Remainder of 2022	$	62,941
2023		73,387
2024		56,654
2025		26,870
Thereafter		3,694
Total undiscounted finance lease payments	$	223,546
Less: Imputed interest		(20,669	)
Present value of finance lease liabilities	$	202,877

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Contractual		Intrinsic
Options	Shares			Price		Term		Value
Balance Outstanding, December 31, 2020		62,000		$	1.19		0.60	$	242,200
Granted		-			-		-		-
Forfeited		-			-		-		-
Exercised		-			-		-		-
Expired		(25,000	)		-		-		-
Balance Outstanding, June 30, 2021		37,000		$	1.32		0.51	$	147,100

Exercisable, June 30, 2021		37,000		$	1.32		0.51	$	147,100

	June 30,		June 30,
Country	2021		2020
France	$	0		0
Germany		3		125,238
Greece		14,504,869		11,967,758
Hungary		0		100
Ireland		0		(9	)
Italy		4		16,007
Jordan		0		(95	)
Denmark		14		0
Cyprus		64,225		0
UK		265,828		697,609
Croatia		11,982		8,617
Libya		0		0
Netherlands		0		4,797
Poland		0		(50	)
Total	$	14,846,925	$	12,819,972

Country	June 30, 2021		June 30, 2020
Croatia	$	11,982	$	8,617
Denmark		54,700		0
France		0		1,091
Germany		13,617		792,540
Greece		25,958,364		22,657,446
Hungary		0		36,240
Ireland		0		35,104
Italy		15,731		22,048
Jordan		0		9,322
Libya				41,972
Netherlands		0		38,252
Poland		0		28,352
Cyprus		78,948		0
UK		332,659		1,082,236
Total	$	26,466,001	$	24,753,220

	·o	Drug shortages due to ban of exports
	·
	o	Problems/restrictions in supply chain
	·	~~Logistics delays~~
	·o	~~National or EU long lasting recession~~ · Logistics delays o Restrictions on employees’ ability to work · o Liquidity issues (AR/AP) – payment delays and new government regulations for freezing payment terms

	o	National or EU long lasting recession

Exhibit No.		Document Description

~~10.1~~		~~Capital Market Advisory Agreement dated July 1, 2021~~

31.1*		Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document**

101.SCH		XBRL Taxonomy Extension Schema Document**

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document**

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document**

101.LAB		XBRL Taxonomy Extension Label Linkbase Document**

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document**

*	This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

**	XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

	Cosmos Holdings Inc.

Date: ~~August 16, 2021~~May 17, 2022	By:	/s/ Grigorios Siokas
		Grigorios Siokas
		Chief Executive Officer
		(Principal Executive Officer)

Date: ~~August 16, 2021~~May 17, 2022	By:	/s/ Georgios Terzis
		Georgios Terzis
		Chief Financial Officer
		(Principal Financial Officer, And Principal Accounting Officer)